WO2021055915A1 - Modified t cells and methods of preparing the same - Google Patents
Modified t cells and methods of preparing the same Download PDFInfo
- Publication number
- WO2021055915A1 WO2021055915A1 PCT/US2020/051713 US2020051713W WO2021055915A1 WO 2021055915 A1 WO2021055915 A1 WO 2021055915A1 US 2020051713 W US2020051713 W US 2020051713W WO 2021055915 A1 WO2021055915 A1 WO 2021055915A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- cells
- modified
- cancer
- tumor
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 356
- 238000000034 method Methods 0.000 title claims abstract description 72
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 147
- 201000011510 cancer Diseases 0.000 claims abstract description 49
- 230000001965 increasing effect Effects 0.000 claims abstract description 28
- 230000006052 T cell proliferation Effects 0.000 claims abstract description 17
- 210000004027 cell Anatomy 0.000 claims description 270
- 108010065637 Interleukin-23 Proteins 0.000 claims description 97
- 102000013264 Interleukin-23 Human genes 0.000 claims description 97
- 230000014509 gene expression Effects 0.000 claims description 55
- 108090000623 proteins and genes Proteins 0.000 claims description 54
- 241000282414 Homo sapiens Species 0.000 claims description 38
- 230000004913 activation Effects 0.000 claims description 38
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims description 34
- 230000000259 anti-tumor effect Effects 0.000 claims description 30
- 230000004083 survival effect Effects 0.000 claims description 18
- 239000006228 supernatant Substances 0.000 claims description 15
- 230000002829 reductive effect Effects 0.000 claims description 13
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 11
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 11
- 201000002528 pancreatic cancer Diseases 0.000 claims description 11
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 11
- 230000037361 pathway Effects 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 230000001177 retroviral effect Effects 0.000 claims description 10
- 230000001105 regulatory effect Effects 0.000 claims description 9
- 102000001398 Granzyme Human genes 0.000 claims description 7
- 108060005986 Granzyme Proteins 0.000 claims description 7
- 201000001441 melanoma Diseases 0.000 claims description 7
- YMZPQKXPKZZSFV-CPWYAANMSA-N 2-[3-[(1r)-1-[(2s)-1-[(2s)-2-[(1r)-cyclohex-2-en-1-yl]-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carbonyl]oxy-3-(3,4-dimethoxyphenyl)propyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H]([C@H]2C=CCCC2)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 YMZPQKXPKZZSFV-CPWYAANMSA-N 0.000 claims description 6
- GTVAUHXUMYENSK-RWSKJCERSA-N 2-[3-[(1r)-3-(3,4-dimethoxyphenyl)-1-[(2s)-1-[(2s)-2-(3,4,5-trimethoxyphenyl)pent-4-enoyl]piperidine-2-carbonyl]oxypropyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H](CC=C)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 GTVAUHXUMYENSK-RWSKJCERSA-N 0.000 claims description 6
- 102100034799 CCAAT/enhancer-binding protein delta Human genes 0.000 claims description 6
- 102000009512 Cyclin-Dependent Kinase Inhibitor p15 Human genes 0.000 claims description 6
- 108010009356 Cyclin-Dependent Kinase Inhibitor p15 Proteins 0.000 claims description 6
- 101000945965 Homo sapiens CCAAT/enhancer-binding protein delta Proteins 0.000 claims description 6
- 101001082065 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 1 Proteins 0.000 claims description 6
- 101001082060 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 3 Proteins 0.000 claims description 6
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 claims description 6
- 101000644847 Homo sapiens Ubl carboxyl-terminal hydrolase 18 Proteins 0.000 claims description 6
- 102100027355 Interferon-induced protein with tetratricopeptide repeats 1 Human genes 0.000 claims description 6
- 102100027302 Interferon-induced protein with tetratricopeptide repeats 3 Human genes 0.000 claims description 6
- 101150043341 Socs3 gene Proteins 0.000 claims description 6
- 102000058015 Suppressor of Cytokine Signaling 3 Human genes 0.000 claims description 6
- 108700027337 Suppressor of Cytokine Signaling 3 Proteins 0.000 claims description 6
- 108700012920 TNF Proteins 0.000 claims description 6
- 102100024270 Transcription factor SOX-2 Human genes 0.000 claims description 6
- 102100020726 Ubl carboxyl-terminal hydrolase 18 Human genes 0.000 claims description 6
- 230000006907 apoptotic process Effects 0.000 claims description 6
- 230000032823 cell division Effects 0.000 claims description 6
- 230000004069 differentiation Effects 0.000 claims description 6
- 230000001976 improved effect Effects 0.000 claims description 6
- 230000026731 phosphorylation Effects 0.000 claims description 6
- 238000006366 phosphorylation reaction Methods 0.000 claims description 6
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 claims description 5
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 101150092476 ABCA1 gene Proteins 0.000 claims description 3
- 102000055510 ATP Binding Cassette Transporter 1 Human genes 0.000 claims description 3
- 108700005241 ATP Binding Cassette Transporter 1 Proteins 0.000 claims description 3
- 108700031361 Brachyury Proteins 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims description 2
- 102000004495 STAT3 Transcription Factor Human genes 0.000 claims 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 77
- 241000699670 Mus sp. Species 0.000 description 48
- 108091008874 T cell receptors Proteins 0.000 description 43
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 43
- 239000000203 mixture Substances 0.000 description 41
- 241001529936 Murinae Species 0.000 description 32
- 101710195550 Interleukin-23 receptor Proteins 0.000 description 31
- 102100036672 Interleukin-23 receptor Human genes 0.000 description 31
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 30
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 28
- 102000004127 Cytokines Human genes 0.000 description 28
- 108090000695 Cytokines Proteins 0.000 description 28
- 238000000540 analysis of variance Methods 0.000 description 27
- 230000000694 effects Effects 0.000 description 26
- 238000010149 post-hoc-test Methods 0.000 description 26
- 241000699666 Mus <mouse, genus> Species 0.000 description 23
- 238000003556 assay Methods 0.000 description 22
- 238000011282 treatment Methods 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 21
- 210000004881 tumor cell Anatomy 0.000 description 21
- 230000000638 stimulation Effects 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- 101000852992 Homo sapiens Interleukin-12 subunit beta Proteins 0.000 description 16
- 241000700159 Rattus Species 0.000 description 15
- 238000001802 infusion Methods 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 13
- 238000011529 RT qPCR Methods 0.000 description 13
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 238000000684 flow cytometry Methods 0.000 description 13
- 210000000952 spleen Anatomy 0.000 description 13
- 239000013598 vector Substances 0.000 description 13
- 101000852980 Homo sapiens Interleukin-23 subunit alpha Proteins 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 230000027455 binding Effects 0.000 description 12
- 206010021143 Hypoxia Diseases 0.000 description 11
- 102100036701 Interleukin-12 subunit beta Human genes 0.000 description 11
- 102100036705 Interleukin-23 subunit alpha Human genes 0.000 description 11
- 239000004698 Polyethylene Substances 0.000 description 11
- 238000010361 transduction Methods 0.000 description 11
- -1 ABCAl Proteins 0.000 description 10
- 206010029260 Neuroblastoma Diseases 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 230000011664 signaling Effects 0.000 description 10
- 230000006044 T cell activation Effects 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000029918 bioluminescence Effects 0.000 description 9
- 238000005415 bioluminescence Methods 0.000 description 9
- 230000000981 bystander Effects 0.000 description 9
- 230000007954 hypoxia Effects 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 230000003252 repetitive effect Effects 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 238000002054 transplantation Methods 0.000 description 9
- 102100026882 Alpha-synuclein Human genes 0.000 description 8
- 108010002350 Interleukin-2 Proteins 0.000 description 8
- 102000000588 Interleukin-2 Human genes 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 230000003305 autocrine Effects 0.000 description 8
- 230000010261 cell growth Effects 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 230000002688 persistence Effects 0.000 description 8
- 210000003289 regulatory T cell Anatomy 0.000 description 8
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 7
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 7
- 108700039887 Essential Genes Proteins 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 238000010199 gene set enrichment analysis Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 230000026683 transduction Effects 0.000 description 7
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 6
- 102000003812 Interleukin-15 Human genes 0.000 description 6
- 108090000172 Interleukin-15 Proteins 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 230000008093 supporting effect Effects 0.000 description 6
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241000288906 Primates Species 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 238000004624 confocal microscopy Methods 0.000 description 5
- 230000000139 costimulatory effect Effects 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 231100000599 cytotoxic agent Toxicity 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 210000000496 pancreas Anatomy 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 241000699800 Cricetinae Species 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 4
- 101000853012 Homo sapiens Interleukin-23 receptor Proteins 0.000 description 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 4
- 108010002586 Interleukin-7 Proteins 0.000 description 4
- 238000003559 RNA-seq method Methods 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 108091027967 Small hairpin RNA Proteins 0.000 description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
- 230000001640 apoptogenic effect Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 239000002254 cytotoxic agent Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 102000057111 human IL23R Human genes 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 108010056030 retronectin Proteins 0.000 description 4
- 239000004055 small Interfering RNA Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 238000011287 therapeutic dose Methods 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 3
- 239000012114 Alexa Fluor 647 Substances 0.000 description 3
- 108090000672 Annexin A5 Proteins 0.000 description 3
- 102000004121 Annexin A5 Human genes 0.000 description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010015548 Euthanasia Diseases 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 3
- 101150002020 Il23a gene Proteins 0.000 description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 230000005754 cellular signaling Effects 0.000 description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 102000050932 human IL12B Human genes 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000010212 intracellular staining Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 2
- 108020004463 18S ribosomal RNA Proteins 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- 208000007860 Anus Neoplasms Diseases 0.000 description 2
- 108010024976 Asparaginase Proteins 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 208000004736 B-Cell Leukemia Diseases 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 206010071602 Genetic polymorphism Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102100040870 Glycine amidinotransferase, mitochondrial Human genes 0.000 description 2
- 101000893303 Homo sapiens Glycine amidinotransferase, mitochondrial Proteins 0.000 description 2
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102100033461 Interleukin-17A Human genes 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241001225883 Prosopis kuntzei Species 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 238000010317 ablation therapy Methods 0.000 description 2
- SAZUGELZHZOXHB-UHFFFAOYSA-N acecarbromal Chemical compound CCC(Br)(CC)C(=O)NC(=O)NC(C)=O SAZUGELZHZOXHB-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000003302 anti-idiotype Effects 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 230000006690 co-activation Effects 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000004940 costimulation Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000000326 densiometry Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940112141 dry powder inhaler Drugs 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000004547 gene signature Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000005746 immune checkpoint blockade Effects 0.000 description 2
- 238000011503 in vivo imaging Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 230000003704 interleukin-23 production Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000013105 post hoc analysis Methods 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- 238000011476 stem cell transplantation Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- CCEKAJIANROZEO-UHFFFAOYSA-N sulfluramid Chemical group CCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CCEKAJIANROZEO-UHFFFAOYSA-N 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- SXFWKZNLYYRHMK-UHFFFAOYSA-N 1h-indolo[7,6-f]quinoline Chemical class C1=CC=C2C3=C(NC=C4)C4=CC=C3C=CC2=N1 SXFWKZNLYYRHMK-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 229930195730 Aflatoxin Natural products 0.000 description 1
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000012110 Alexa Fluor 594 Substances 0.000 description 1
- 239000012117 Alexa Fluor 700 Substances 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 101100378758 Anemone leveillei AL21 gene Proteins 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000282672 Ateles sp. Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 102100037140 BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like Human genes 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 241000157302 Bison bison athabascae Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102100029145 DNA damage-inducible transcript 3 protein Human genes 0.000 description 1
- 102100026139 DNA damage-inducible transcript 4 protein Human genes 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000271571 Dromaius novaehollandiae Species 0.000 description 1
- 102100037249 Egl nine homolog 1 Human genes 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102100036448 Endothelial PAS domain-containing protein 1 Human genes 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 229940125497 HER2 kinase inhibitor Drugs 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000740545 Homo sapiens BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000912753 Homo sapiens DNA damage-inducible transcript 4 protein Proteins 0.000 description 1
- 101000881648 Homo sapiens Egl nine homolog 1 Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101000686034 Homo sapiens Nuclear receptor ROR-gamma Proteins 0.000 description 1
- 101000881678 Homo sapiens Prolyl hydroxylase EGLN3 Proteins 0.000 description 1
- 101000797623 Homo sapiens Protein AMBP Proteins 0.000 description 1
- 101000713602 Homo sapiens T-box transcription factor TBX21 Proteins 0.000 description 1
- 101000777646 Homo sapiens Uncharacterized protein encoded by LINC01587 Proteins 0.000 description 1
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 101150030333 Il12b gene Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 206010024291 Leukaemias acute myeloid Diseases 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000283923 Marmota monax Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- PKFBJSDMCRJYDC-GEZSXCAASA-N N-acetyl-s-geranylgeranyl-l-cysteine Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CSC[C@@H](C(O)=O)NC(C)=O PKFBJSDMCRJYDC-GEZSXCAASA-N 0.000 description 1
- 206010028729 Nasal cavity cancer Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 101150026055 Ngfr gene Proteins 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000010505 Nose Neoplasms Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- 102100037247 Prolyl hydroxylase EGLN3 Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100032859 Protein AMBP Human genes 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 101150099493 STAT3 gene Proteins 0.000 description 1
- 102000001712 STAT5 Transcription Factor Human genes 0.000 description 1
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000032383 Soft tissue cancer Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108010091885 T-box transcription factor TBX21 Proteins 0.000 description 1
- 102100036840 T-box transcription factor TBX21 Human genes 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108010057666 Transcription Factor CHOP Proteins 0.000 description 1
- 108010005656 Ubiquitin Thiolesterase Proteins 0.000 description 1
- 102000005918 Ubiquitin Thiolesterase Human genes 0.000 description 1
- 102100031590 Uncharacterized protein encoded by LINC01587 Human genes 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046392 Ureteric cancer Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 102100024148 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000002487 adenosine deaminase inhibitor Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 206010065867 alveolar rhabdomyosarcoma Diseases 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- 201000007696 anal canal cancer Diseases 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 238000011130 autologous cell therapy Methods 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 241001233037 catfish Species 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000015861 cell surface binding Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000011198 co-culture assay Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 108010018033 endothelial PAS domain-containing protein 1 Proteins 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000002710 external beam radiation therapy Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 201000007487 gallbladder carcinoma Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 102000055061 human IL23A Human genes 0.000 description 1
- 102000047214 human RORC Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000011246 intracellular protein detection Methods 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 210000003228 intrahepatic bile duct Anatomy 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 201000004962 larynx cancer Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 208000025848 malignant tumor of nasopharynx Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 208000006971 mastocytoma Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 201000003956 middle ear cancer Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229940014456 mycophenolate Drugs 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 201000007425 nasal cavity carcinoma Diseases 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000002747 omentum Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 201000008006 pharynx cancer Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 201000003437 pleural cancer Diseases 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000513 principal component analysis Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000020874 response to hypoxia Effects 0.000 description 1
- 230000022120 response to tumor cell Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229960003452 romidepsin Drugs 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- 102220056978 rs730880472 Human genes 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000011222 transcriptome analysis Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229950001353 tretamine Drugs 0.000 description 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
- 150000004654 triazenes Chemical class 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 201000011294 ureter cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4635—Cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464469—Tumor associated carbohydrates
- A61K39/464471—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/54—Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Abstract
Disclosed herein are modified T cells comprising an IL12β p40 subunit. Also disclosed herein are methods of increasing T cell proliferation and/or methods of treating cancer by administering the modified T cells comprising an IL12β p40 subunit.
Description
MODIFIED T CELLS AND METHODS OF PREPARING THE SAME
RELATED APPLICATIONS
This application claims the benefit of U.S. Provisional Application Serial No. 62/903,717, filed September 20, 2019, the contents of which is hereby incorporated by reference in its entirety.
GOVERNMENT SUPPORT
This invention was made with government support under Grant Number CA193140 awarded by the National Institutes of Health. The government has certain rights in the invention.
BACKGROUND OF THE INVENTION
T cells are a main focus for cancer immunotherapies due to their potent anti tumor activity. While most endogenous T cells in cancer patients are either non- responsive or dysfunctional [1], they can be armed via genetic engineering with a tumor-targeting T cell receptor (TCR) or a chimeric antigen receptor (CAR) [2] TCR and CAR-engineered T cells promote substantial objective clinical responses in synovial carcinoma [3] and B cell lymphoid malignancies [4], respectively. In particular, CAR-expressing T cells expand in vivo in patients with B cell leukemia and can persist up to 24 months post infusion [5] In contrast, T cell expansion and persistence within the tumor microenvironment (TME) is usually hindered in solid tumors by multiple factors such as checkpoint inhibition [6] and metabolic starvation [1]·
T cell proliferation requires optimal T cell activation, which integrates signals downstream of the T cell receptor (TCR)/CD3 complex, engagement of costimulatory molecules and cytokines [7] CAR-based engineering provides the first two factors, while TCR-based engineering remains challenging in providing adequate costimulation [7] However, for both TCR and CAR engineering strategies, the
cytokine component remains a significant limiting factor, as the only cytokine secreted by engineered T cells is IL2, which may support the activation and expansion of regulatory T cells (Tregs) [8] Additional engineering of CAR T cells with common g chain cytokines such as IL15 is effective in supporting their proliferation and effector function, while the effects on Tregs are limited [9, 10] However, cytokine engineering can lead to side effects, as they are constitutively produced and their receptor is expressed by most T cells and natural killer (NK) cells, requiring the inclusion of safety switches to contain potential toxic effects [11-13] Thus, the development of inducible and selective engineering processes supporting T cell expansion and survival within the TME remains critical in adoptive T cell therapies in solid tumors.
SUMMARY OF THE INVENTION
Described herein are novel strategies for incorporating a highly regulated cytokine signaling into tumor-specific T cells to improve their efficacy. This approach has significant translational potential since it can be used for both CAR- and TCR- engineered T cells. IL23 has been identified as having selective proliferative activity in activated T cells when its p40 subunit is engineered in T cells. The proposed manipulated IL23/IL23R axis not only promotes T cell proliferation and anti-tumor activity upon T cell activation, but also limits the effects on bystander cells due to a specific autocrine mode of action.
Disclosed herein are modified T cells comprising an IL12P p40 subunit.
In some embodiments the T cell expresses p40. In some embodiments the T cell exhibits increased cell division. In some embodiments the T cell exhibits reduced apoptosis. In some embodiments the T cell exhibits increased T cell proliferation. In some embodiments the T cell expresses high levels of lytic enzyme granzyme B, as compared to a control cell. In some embodiments the T cell expresses reduced levels of exhaustion markers PD1 and/or CD101, as compared to a control cell. In some embodiments the T cell maintains production of IFNy and TNFa, as compared to a control cell.
In some embodiments, the T cell, upon activation, produces IL23. In some embodiments the T cell, upon activation, exhibits increased STAT3 phosphorylation.
In some embodiments the T cell, upon activation, exhibits differentiation expression of one or more STAT3 regulated genes selected from the group consisting of: SOX2, SOCS3, CEBPD, ABCA1, IFIT1, IFIT3, USP18, CDKN2B, and combinations thereof. In some embodiments the T cell, upon activation, activates the STAT3 pathway.
In some embodiments the T cell promotes enhanced tumor control and improved survival, as compared to a control cell. In some embodiments the T cell exhibits increased anti-tumor activity. Methods for improving or increasing any of the desirable effects on T cells described herein are also encompassed by the invention.
In some embodiments the T cell is a human T cell. In some embodiments the T cell is a non-human T cell. In some embodiments the T cell is a mouse T cell. In some embodiments the T cell is a CAR or TCR-engineered T cell.
In some embodiments the T cell comprising the IIA2b p40 subunit is produced by transducing a T cell with a retroviral supernatant comprising an ILl 2b p40 subunit.
Also disclosed herein are methods of increasing T cell proliferation. The methods comprise modifying a T cell to comprise an IIA2b p40 subunit.
Also disclosed herein are methods of treating cancer. The methods comprise administering to a subject a modified T cell comprising an IL l 2b p40 subunit.
In some embodiments upon activation of the modified T cell, the modified T cell produces IL23.
In some embodiments the modified T cell exhibits increased anti-tumor activity. In some embodiments the modified T cell exhibits increased T cell proliferation. In some embodiments the modified T cell promotes tumor regression.
In some embodiments the modified T cell protects from tumor re-challenge.
In some embodiments the cancer is a melanoma. In some embodiments the cancer is a pancreatic cancer. In some embodiments the cancer is a hematologic malignancy. In some embodiments the cancer is a multiple myeloma. In some embodiments the cancer is a carcinoma or a sarcoma. In some embodiments the tumor is a solid tumor.
In some embodiments the subject is a mammal (e.g., a human).
BRIEF DESCRIPTION OF THE DRAWINGS
The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawings will be provided by the Office upon request and payment of the necessary fee.
FIGS. 1A-1N demonstrate IL23 supports the expansion of T cells in an activation-inducible dependent manner. FIGS. 1A-1B show IL23R expression at mRNA (FIG. 1 A) and protein level (FIG. IB) measured by qRT-PCR and western blot, respectively in human T cells activated and expanded ex vivo (CX-TM) at time 0, 24, 48 hours after TCR activation. Data are represented as fold change in expression normalized to the housekeeping gene 18S and to the expression at time 0. Data shown are individual values and mean ± SD (n = 6 in (a) and n = 5 in (b)). FIG. 1C shows expansion of ex-TM with or without activation with aCD3 and aCD28 Abs and with or without rIL23 (50 ng/mL). Cell numbers were numerated by flow cytometry at day 7. Data shown are individual values and mean ± SD (n = 4), ***p=0.0002 determined by repeated measured 2-way ANOVA with Sidak post hoc test. FIG. ID shows distribution of CD4+ and CD8+ T cells in CX-TM activated with aCD3 and aCD28 Abs in the presence or absence of 50 ng/mL rIL23 at day 7. Data shown as mean ± SD (n = 4). FIG. IE shows intracellular detection of IFN-g and IL-17 in CD4+ and CD8+T cells in CX-TM activated with aCD3 and aCD28 Abs in the presence or absence of 50 ng/mL rIL23 for 7 days. Data shown as or individual values, mean ± SD (n = 4). FIG. IF shows relative expression of the Thl7 and Thl transcription factor RORyT and Tbet, respectively assessed by qRT-PCR in CX-TM activated with aCD3 and aCD28 Abs in the presence or absence of 50 ng/mL rIL23 for 7 days. Data shown as individual values, mean ± SD (n = 4). FIG. 1G shows mRNA expression of the IL23 subunits pl9 ( IL23A ) and p40 ( IL12B ) in CX-TM activated with aCD3 and aCD28 Abs at time 0, 24, 48 hours as determined by qRT-PCR. Data are expressed as fold change in expression normalized to the housekeeping gene 18S and to the expression at time 0. Error bars denote SD (n = 4). FIG. 1H shows detection of IL23 secreted by Ctrl cells or p40-Td cells activated with aCD3 and aCD28 Abs for 0, 24 and 48 hours as measured by ELISA. Data shown as individuals and mean ± SD (n = 5). ****p<0.0001 determined by repeated measured 2-way ANOVA with Sidak post hoc test. FIG. II shows numeric expansion of Ctrl cells and p40-Td cells activated with
aCD3 and aCD28 Abs. Data shown as mean ± SD (n = 13). ***p=0.0006, ****r<0.0001 determined by repeated measured 2-way ANOVA with Sidak post hoc test. FIG. 1J shows detection of IL23 secreted by activated Ctrl cells and p40-Td cells co-transduced with either the vector encoding control shRNA (sh-Ctrl cells) or IL23 A- shRNA (sh-IL23 A). Data shown as individual values and mean ± SD (n = 3). ***p=0.0002 determined by repeated measured 2-way ANOVA with Sidak post hoc test. FIG. IK shows cell counts at day 5 of sh-Ctrl cells or sh-IL23 A cells activated with aCD3 and aCD28 Abs. Data shown as individual values and mean ± SD (n = 4). **p=0.0069 for Ctrl cells:sh-Ctrl cells vs. p40-Td cells:sh-Ctrl cells and **p=0.0056 for p40:sh-Ctrl cells vs. p40-Td cells:sh-IL23A, determined by repeated measured 2- way ANOVA with Sidak post hoc test. FIG. 1L shows expression (transcript per million) of IL23A (left) and IL12B (right) mRNA in tumor (red dots) and adjacent normal tissues (green dots) from different cancer patients plotted using TCGA data. Tumor types highlighted in red indicate higher expression in tumor tissues vs. normal tissues, while those highlighted green indicate lower expression. FIG. 1M shows expression of IL23A and IL12B genes determined by qRT-PCR in breast cancer (BC), colon rectal cancer (CRC) and pancreatic cancer (PC) and paired adjacent normal tissues. Data are shown as copies of RNA per 50 ng RNA (n = 6). Dotted line indicates the detection limit of the qRT-PCR assay used (CT>35). **p=0.0019 was determined by 1-way ANOVA with Sidak post hoc test. FIG. IN shows detection of IL23 by ELISA in the supernatant of single cell suspension of paired tumors and adjacent normal tissues. Data are shown as pg of IL23 per 100 pg supernatant protein input (n = 6).
FIGS. 2A-2H demonstrate T cell receptor activation induces STAT3 and hypoxia gene signature in p40-Td cells. FIG. 2 A provides a volcano plot of gene expression before (left) and 5 days after activation (right) with aCD3 and aCD28 Abs of Ctrl and p40-Td cells. Volcano plot was constructed using log2fold change and - logio(FDR) of all genes. Red dots represent genes with more than 2-fold change (up or down) and FDR<0.01. FIG. 2B shows number of differentially expressed genes before and after stimulation of Ctrl and p40-Td cells. FIG. 2C provides principal component analysis (PC A) of activated Ctrl and p40-Td cells. FIG. 2D shows GSEA for the expression profiles of the activated Ctrl cells as compared to activated p40-Td
cells using “STAT3 upregulated” (up) and “STAT3 downregulated” (down) gene sets and the expression heatmap of genes in the gene sets. FIG. 2E provides representative western blot showing Ser727 and Tyr705 phosphorylation of STAT3 in Ctrl cells and p40-Td cells before and 5 days after stimulation with aCD3 and aCD28 Abs (upper panel). Densitometry of pSTAT3 (lower panel), mean ± SD (n = 5). ***p=0.0001 determined by repeated measured 2-way ANOVA with Sidak post hoc test. FIG. 2F shows qRT-PCR quantification of upregulated (red) or downregulated (down) genes STAT3 pathway related. Data were first normalized to housekeeping gene 18S and the mean ± SD log2fold change of gene expression of activated Ctrl vs. p40-Td cells (n = 4) were shown. FIG. 2G shows GSEA for the expression profiles of activated Ctrl and p40-Td cells using “hallmark of hypoxia” gene set (left panel) and expression heatmap of genes in the gene sets (right panel). FIG. 2H shows qRT-PCR quantification of hypoxia pathway related genes in activated Ctrl and p40-Td cells. Data were first normalized to housekeeping gene 18S and then to the expression level to Ctrl cells (n = 4).
FIGS. 3 A-3P demonstrate that p40 expression enhances the anti-tumor activity of CAR T cells in a neuroblastoma model. FIGS. 3A-3B provide counts of neuroblastoma tumor cells (LAN-1 and CHLA-255) after each round of repetitive coculture (Rl, R2 and R3) with either control T cells (Ctrl.), GD2-specific CAR T cells (CAR-Ctrl) or GD2-specific CAR T cells coexpressing p40 (CAR.p40-Td). Data shown as individual values and mean ± SD (n = 8). ****p<0.0001 determined by repeated measure 2-way ANOVA with Sidak post hoc test. FIGS. 3C-3D provide T cell counts after each round of repetitive coculture illustrated in FIGS. 3A-3B. Data shown as individual values and mean ± SD (n = 8). *p=0.03 for LAN1 R2; **p=0.0049 for LAN1 R3; ***p=0.0003 for CHLA-255 R2; **p=0.0091 for CHLA- 255 R3 determined by repeated measure 2-way ANOVA with Sidak post hoc test.
FIG. 3E shows intracellular staining of granzyme B of CAR. Ctrl cells and CAR.p40- Td cells at the end of Rl. Data shown as individual values and mean ± SD (n = 3). **p=0.0052 determined by paired t test. FIG. 3F shows expression of PD1 and CD101 in CAR. Ctrl cells and CAR.p40-Td cells after Rl and R2 of repetitive coculture with LAN-1 tumor cells. Data shown as individual values and mean ± SD (n = 3). **p=0.0014 for PD1 R2; *p=0.0365 for CD101 R2. FIG. 3G shows intracellular
staining of IFN-g and TNF-a of CAR. Ctrl cells and CAR.p40-Td cells at the end of Rland R2 of coculture with LAN1 tumor cells. Data shown as individual values and mean ± SD (n = 3). **p=0.002 for IFN-y+ cells at Rl; *p=0.0409 for IFN-y+TNF-oC cells at Rl; ****p<0.0001 for IFN-y+ cells at R2; **p=0.009 for IFN-Y+TNF-a+ cells at R2 determined by repeated measure 2-way ANOVA with Sidak post hoc test. FIG. 3H provides a schematic representation of the metastatic neuroblastoma xenograft model. FIG. 31 shows representative tumor bioluminescence (BLI) of 2 independent experiments (n = 8 mice/group). FIG. 3 J shows kinetics of tumor BLI of 2 independent experiments (n = 8 mice/group). Solid lines delineate mean fold change over time, while dashed lines indicate data of each individual mouse. FIG. 3K shows Kaplan-Meier survival curve summarizing 2 independent experiments (n = 8 mice/group). FIG. 3L shows frequency of human CD3+CD45+ cells in blood, spleen and liver collected 10 days post T cell infusion. Data shown as individual values, mean ± SD (n = 5 mice/group) and are representative of 2 experiments. ***p=0.0006 for blood; ****p<0.0001 for liver and p=0.0007 for spleen determined by 1-way ANOVA with Sidak post hoc test. FIG. 3M shows frequency of human CD3+CD45+ cells in blood, spleen and liver collected at the time of mouse euthanasia. Data shown as individual values, mean ± SD (n = 5 mice/group) and are representative of 2 experiments. *p=0.0132 for blood; **p<0.0067 for liver and p=0.0071 for spleen determined by 1-way ANOVA with Sidak post hoc test. FIG. 3N provides a schematic representation of the metastatic neuroblastoma xenograft model and tumor rechallenge. FIG. 30 shows representative tumor BLI of 2 independent experiments (n = 8 mice/group). FIG. 3P provides kinetics of tumor BLI of 2 independent experiments (n = 8 mice/group). Solid lines delineate mean fold change over time, while dashed lines indicate data of each individual mouse.
FIGS. 4A-4G demonstrate that p40 expression enhances the anti-tumor activity of CAR T cells in a pancreatic cancer model. FIG. 4A provides counts of pancreatic cancer cell (BXPC-3) after each round of repetitive coculture (Rl, R2 and R3) with either control T cells (Ctrl.), B7-H3-specific CAR T cells (CAR-Ctrl) or B7- FB-specific CAR T cells coexpressing p40 (CAR.p40-Td) at T cell to tumor cell ratios 1:2 (left panel) or 1:5 (right panel). Data shown as individual values, mean ±
SD (n = 6). ***: p=0.0003, ****; p<0.0001 determined by repeated measured 2-way
ANOVA with Sidak post hoc test. FIG. 4B provides T cell counts after each round of repetitive coculture illustrated in FIG. 4A. Data shown as individual values and mean ± SD (n = 6). *: p=0.0195 for R2, p=0.021 for R3, **: p=0.0024, ****: p<0.0001 determined by repeated measured 2-way ANOVA with Sidak post hoc test. FIG. 4C provides a schematic of the orthotopic pancreatic cancer model. FIG. 4D shows representative tumor BLI of 2 independent experiments (n = 8 mice/group). FIG. 4E provides kinetics of tumor BLI of 2 independent experiments (n = 8 mice/group).
Solid lines delineate mean fold change over time, while dashed lines indicate data of each individual mouse. FIG. 4F provides Kaplan-Meier survival analysis of 2 independent experiments (n= 8 mice/group. FIG. 4G shows frequency of human CD3+CD45+ cells in blood, spleen and pancreas collected from mice at day 60 post T cell infusion. Data shown as individual values, mean ± SD (n = 7 mice/group **: p=0.0017 for blood, p=0.00065 for spleen and p=0.0014 for tumor) determined by unpaired Student t-test.
FIGS. 5A-5K demonstrate that p40 expression enhances the anti-tumor activity of T cells in syngeneic tumor models. FIGS. 5A-5B shows expression of IL23A, IL12B (FIG. 5 A) andIL23R (FIG. 5B) genes determined by qRT-PCR in ex vivo activated and expanded murine splenic T cells after re-stimulation with aCD3 and aCD28 Abs for 0, 24 and 48 hours. Data shown as fold change in gene expression normalized to the housekeeping gene CD3E and to the value at time 0. Data shown are individual values and mean ± SD (n = 4). FIG. 5C provides measurement of murine IL23 released by murine splenic T cells transduced either with the empty vector (EV) or the vector encoding murine IL12B gene (mp40-Td) and re-stimulated with aCD3 and aCD28 Abs for 0, 24 and 48 hours. Data shown are individual values and mean ± SD (n = 8). FIG. 5D provides cell counts of EV and mp40-Td murine T cells at day 1, 3 and 5 after re-stimulation with aCD3 and aCD28 Abs. Data shown are mean ± SD (n = 3). ****; p<0.0001 determined by repeated measured 2-way ANOVA with Sidak post hoc test. FIG. 5E provides a schematic of the syngeneic B16 melanoma model. FIG. 5F provides measurement of the tumor volume post T cell injection. Data shown as mean ± SD of 2 independent experiments (n = 7/8 mice/group) for lxl 06 T cell group and of 1 experiment (n=3/4 mice/group) for lxl 06 T cell group. *: p=0.0182; ***: p=0.0007; ****:p<0.0001 determined by 2-way
ANOVA with Sidak post hoc test. FIG. 5G shows detection of murine IL23 in the serum and tumor supernatant collected 14 days after T cell infusion. FIG. 5H shows frequency of OT1 TCR+ (Va2+Vb5+) cells within the CD8+ T cells in the tissues collected from treated mice. Data shown as mean ± SD (n = 5 mice/group). ****r<0.0001 determined by 2-way ANOVA with Sidak post hoc test. FIG. 51 shows immune composition of the peripheral blood, spleen, draining lymph nodes (dLN) and tumor at the time of euthanasia. Data shown as individual values and mean ± SD of 2 independent experiments (n = 9 mice/group). FIG. 5J provides a schematic of the syngeneic PD AC orthotopic model. Murine cell line KPC-4662 engineered to express murine B7-H3 (KPC-mB7-H3) was implanted (0.1 x 106 cells/mouse) into the pancreas of 6 week old C57BL/6 mice. Eighteen days post tumor cell implantation, mice were irradiated with 400 cGy and 3 days later infused i.v. with syngeneic B7- H3.CAR.EV cells (1 c 107 cells/mouse) or B7-H3.CAR.mp40-Td cells (1 c 107 cells/mouse). Tumor growth was monitored by US. FIG. 5K provides a summary of the fold change (compared to day 0) in tumor volume (n = 5 mice/group). **p = 0.0068 determined by 2-way ANOVA with Sidak post hoc test between B7- H3.CAR.EV vs B7.H3.CAR.mp40-Td at Day 42.
FIGS. 6A-6M demonstrate engineered IL23 functions predominantly through an autocrine mode of action. FIG. 6A provides schematics of the co-activation experiment with p40-Td cells and ACD19-Td cells. FIG. 6B provides a representative plot ofNGFR+ (p40-Td cells) and CD 19+ (bystander cells) at days 0 and 5 post activation. FIG. 6C shows cell number and percentage of NGFR+ and CD19+ cells 5 days post-activation. Data shown as individual values and mean ± SD (n = 5). Dotted line indicates starting cell number and percentage, respectively. ****p<0.0001 determined by paired Student t test. FIG. 6D provides representative western blot showing the expression of IL23R in ACD19-Td and p40-Td cells at days 1 or 3 after activation (n = 5). FIG. 6E provides a schematic of the sequential coculture of GD2- specific CAR T cells coexpressing either ACD19 (CAR.ACD19-Td) or p40 (CAR.p40-Td) with the LAN-1 tumor cell line. FIG. 6F shows percentages of NGFR+ and CD19+ CAR T cells detected at the end of the first (Rl) and second (R2) round of coculture. Data shown as individuals and mean ± SD (n = 6). ****; p<0.0001 determined by repeated measured 2-way ANOVA with Sidak post hoc test. FIG. 6G
provides a flow plot illustrating the coexpression of NGFR and GFP (left panel) and detection of IL23 in the supernatant (right panel) of T cells transduced with a vector encoding the p40-GFP fusion protein. Data shown as mean ± SD (n = 4). FIG. 6H provides a schematic and staining procedure of the co-activation experiment with p40-GFP and ACD l 9-Td cells. FIG. 61 provides representative flow histograms showing the surface binding of the p40-GFP protein on CD19+ or NGFR+ T cells. Individual values and mean ± SD (n = 5). ***p=0.0003 determined by paired Student t test. FIG. 6J provides representative confocal microscopy imaging (left panel) showing the surface binding of p40-GFP protein in CD19+ or NGFR+ cells and quantification of fluorescence intensity of the surface GFP signal for >50 CD19+ or NGFR+ cells (left panels) (n = 5). FIGS. 6K-6L show surface binding of p40-GFP in p40-GFP-Td in the absence or presence of the soluble recombinant human IL23R ( L23R) determined by flow cytometry (FIG. 6K) and confocal microscopy (FIG. 6L). Data are presented as individual values and mean ± SD of >50 analyzed cell images (n = 5). FIG. 6M shows T cell numbers of Ctrl cells or p40-Td cells at day 5 post-activation with aCD3/aCD28 Abs in the absence or in the presence of soluble rhIL23R. Data are presented as individual values and mean ± SD (n = 6).
***p=0.0006 determined by repeated measure 2-way ANOVA with Sidak post hoc test.
FIGS. 7A-7E provide a phenotypic analysis of p40-Td cells. FIG. 7 A provides a schematic representation of the retroviral vectors (upper panel) and representative flow cytometry plots illustrating the transduction efficiency on T cells measured by DNGFR expression and qRT-PCR. Data shown as representative data and mean ± SD (n =4 ). FIG. 7B shows cell counts of Ctrl or p40-Td cells cultured with IL-7 and IL- 15. DNGFR+ cells were sorted on day 5 post-transduction. Data shown as mean ± SD (n = 4). FIG. 7C shows frequency of CD4+ and CD8+ T cells of Ctrl and p40-Td cells at day 12 post-transduction. Data shown as representative data and mean ± SD (n =
4). FIG. 7D provides representative flow cytometry plots illustrating the expression of memory markers in Ctrl and p40-Td cells at day 12 post-transduction (n = 4). FIG. 7E shows mean fluorescence intensity (MFI) of exhaustion and inhibitory receptors in Ctrl and p40-Td cells at day 12 post-transduction. Data shown as mean±SD (n = 4).
FIGS. 8A-8D demonstrate p40-Td cells show superior proliferation and survival upon activation. FIG. 8 A shows expression of Ki67+ cells in CD4+ and CD8+ T cells of Ctrl or p40-Td cells stimulated with aCD3 and aCD28 Abs for 3 days. Data shown as individual value, mean ± SD (n = 5). p value determined by repeated measure 2-way ANOVA with Sidak post hoc test. p=0.0051 for CD4+ and p=0.0038 for CD8+ T cells. FIG. 8B provides expansion index of CellTrace Violet labeled Ctrl or p40-Td cells stimulated with aCD3 and aCD28 Abs for 5 days. Data shown as individual value, mean ± SD (n = 3). p value determined by repeated measure 2-way ANOVA with Sidak post hoc test. p=0.0056 for CD4+ and p=0.0014 for CD8+ T cells. FIG. 8C provides representative flow plots (left panel) and summary (right panel) of Annexin V and 7AAD staining of Ctrl or p40-Td cells stimulated with aCD3 and aCD28 Abs for 5 days. Data shown as individual value, mean ± SD (n = 4). p value determined by repeated measure 2-way ANOVA with Sidak post hoc test. p<0.0001 for live, ns for early apoptotic and p<0.0001 for late apoptotic.
FIGS. 9A-9E demonstrate that p40 expression enhances the anti-tumor activity of CAR T cells in neuroblastoma. FIG. 9A provides representative flow plots (left panel) and summary (right panel) illustrating the co-expression of CAR and ANGFR in Ctrl and GD2-specific CAR-Ts expressing p40. Data shown individual values, mean ± SD (n = 4). FIG. 9B provides T cell counts of GD2-specific CAR. Ctrl cells or CAR.p40-Td cells activated by plate-bound anti-idiotype 1 A7 Ab. Data shown as mean ± SD (n = 5). ****p<0.0001 determined by repeated measure 2-way ANOVA with Sidak post hoc test. FIG. 9C shows frequency of apoptotic cells in CAR. Ctrl cells and CAR.p40-Td cells activated by the 1 A7 Ab for 5 days using the Annexin V/7AAD staining. Data shown as individual values and mean ± SD (n = 4). ***p=0.0006 for live cells; ***p=0.0005 for late apoptotic cells p values were determined by repeated measure 2-way ANOVA with Sidak post hoc test. FIG. 9D shows detection of IL23 and IL2 in the supernatant of CAR. Ctrl cells and CAR.p40- Td cells post-stimulation with the 1 A7 Ab stimulation. Data shown as individual values and mean ± SD (n = 3). FIG. 9E provides a schematic of the repetitive coculture experiment.
FIG. 10 demonstrates that recombinant human IL23R (rhIL23R) sequesters IL23. Supernatant of Ctrl or p40-Td cells were incubated with murine splenocytes
with or without rhIL23R. Murine IL17 release by the splenocytes in response to IL23 was measured by ELISA. Data are presented as individual values and mean ± SD (n = 4). *p=0.0122 for Ctrl cells vs. p40-Td cells; *p=0.0308 for p40-Td cells vs. p40-Td cells plus rhIL23R. p values were determined by repeated measure 1-way NAOVA with Sidak post hoc test.
DETAILED DESCRIPTION OF THE INVENTION
One of the benefits of adoptive T cell immunotherapies for cancer is the ability of the infused T cells to proliferate upon tumor engagement and establish immunological memory to prevent tumor relapse. However, both T cell proliferation and effector function are hampered by immunosuppressive factors within the tumor microenvironment (TME). Proliferative cytokines (e.g., IL2 and IL15) support T cell division and anti-tumor activity, but the incorporation of cytokines into tumor specific T cells comes with various risks due to the constitutive cytokine signaling in T cells and activation of bystander cells that may further increase toxicity or reduce efficacy. IL23 is described herein as having a selective proliferative activity in activated T cells when its p40 subunit is engineered in T cells. The proposed manipulated IL23/IL23R axis not only promotes T cell proliferation and anti-tumor activity upon T cell activation, but also limits the effects on bystander cells due to a specific autocrine mode of action.
Described herein are modified T cells, compositions comprising the modified T cells, and therapeutic methods using the modified T cells. The modified T cells described herein exhibit enhanced anti-tumor activity, including enhanced proliferation.
Modified T Cells
Aspects of the disclosure relate to modified T cells. In some embodiments, the modified T cells are tumor specific T cells that comprise an IL23a pl9 subunit and an IL12P p40 subunit. In some embodiments, the modified T cell is a chimeric antigen receptor (CAR)-engineered T cell. In some embodiments, the modified T cell is a T-cell receptor (TCR)-engineered T cell. In some aspects, the modified T cells express p40. In some embodiments, a modified T cell produces IL23 upon activation
(e.g., TCR or CAR activation). It is generally understood that both IL23a pl9 subunit and ILl 2b p40 subunit must be present for the T cell to produce and release IL23. In some embodiments, the production of IL23 has been shown to drive T cell proliferation and survival.
In some embodiments, the T cell is a human T cell or a non-human T cell. In some embodiments mammalian cells are used. In some embodiments mammalian cells are primate cells (human cells or non-human primate cells), rodent (e.g., mouse, rat, rabbit, hamster) cells, canine, feline, bovine, or other mammalian cells. In some embodiments avian cells are used. In some embodiments, the T cells are tumor- specific T cells.
In some embodiments, the T cell is a abT cell, a cytotoxic T lymphocyte (CTL), a regulatory T cell, a natural killer T (NKT) cell, a Thl7 cell, a gdT cell, or any combination thereof. In some embodiments, the T cell is an autologous cell. In some embodiments, the T cell is not an autologous cell. In some embodiments, the T cell is of the same species of a subject. In some embodiments, the T cell is of a species that is different than the species of a subject.
In certain embodiments a modified T cell is engineered to comprise both an IL23a pl9 subunit and an IL l 2b p40 subunit that, upon activation, produces IL23. In some aspects the modified T cell further includes part or all of a cytoplasmic signaling domain of Oϋ3z chain, and/or part or all of one or more costimulatory molecules, such as CD28, 4 IBB, and 0X40. In some aspects the modified T cell further includes a cytoplasmic signaling domain of Oϋ3z chain. In some aspects the modified T cell further includes a portion of a cytoplasmic signaling domain of Oϋ3z chain. In some aspects the modified T cell further includes a costimulatory molecule selected from the group consisting of CD28, 4 IBB, 0X40, and combinations thereof. In some aspects the modified T cell further includes a portion of a costimulatory molecule selected from the group consisting of CD28, 4 IBB, 0X40, and combinations thereof.
The modified T cells described herein exhibit one or more features. Non limiting examples of the features of the modified T cells include increased cell division, reduced apoptosis, increased T cell proliferation, increased STAT3 phosphorylation (upon activation), exhibits differentiation expression of one or more STAT3 regulated genes (e.g, SOX2, SOCS3, CEBPD, ABCAl, IFIT1, IFIT3,
USP18, CDKN2B, and combinations thereof), activates the STAT3 pathway (upon activation), expresses high levels of lytic enzyme granzyme B (as compared to a control cell), expresses reduced levels of exhaustion markers PD1 and/or CD101 (as compared to a control cell), maintains production of IFNy and TNFa (as compared to a control cell), promotes enhanced tumor control and improved survival (as compared to a control cell), exhibits increased anti-tumor activity, and combinations thereof. In some embodiments, the modified T cell exhibits increased cell division. In some embodiments, the modified T cell exhibits reduced apoptosis. In some embodiments, the modified T cell exhibits increased T cell proliferation. In some embodiments, the modified T cell, upon activation, exhibits increased STAT3 phosphorylation. In some embodiments, the modified T cell exhibits differentiation expression of one or more STAT3 regulated genes selected from the group consisting of: SOX2, SOCS3, CEBPD, ABCAl, IFIT1, IFIT3, USP18, CDKN2B, and combinations thereof. In some embodiments, the modified T cell, upon activation, activates the STAT3 pathway. In some embodiments, the modified T cell expresses high levels of lytic enzyme granzyme B, as compared to a control cell. In some embodiments, the modified T cell expresses reduced levels of exhaustion markers PD1 and/or CD101, as compared to a control cell. In some embodiments, the modified T cell maintains production of IFNy and TNFa, as compared to a control cell. In some embodiments, the modified T cell promotes enhanced tumor control and improved survival, as compared to a control cell. In some embodiments, the modified T cell exhibits increased anti-tumor activity.
In some embodiments T cells are isolated from a mammal and genetically modified (i.e., transduced or transfected in vitro) with the IL l 2b p40 subunit. In some embodiments, a T cell can be transduced with a viral vector or transfected with a plasmid or nucleic acid construct. In some embodiments, the modified T cell is a tumor specific T cell that is transduced with a retroviral supernatant comprising an IL12P p40 subunit. In some embodiments, an IIA2b p40 subunit is supplemented to a T cell using gamma retroviral transduction. In some aspects, the modified T cells are activated in response to TCR or CAR stimulation.
For administration to a subject, modified T cells produced by the methods as disclosed herein can be administered to a subject, for example in pharmaceutically
acceptable compositions. These pharmaceutically acceptable compositions comprise a therapeutically-effective amount of modified T cells as described above, formulated together with one or more pharmaceutically acceptable carriers (additives) and/or diluents. In some embodiments the pharmaceutical compositions comprising the modified T cells further include diluents and/or other components, such as IL2, and/or other cytokines and/or cell populations.
As described herein, the pharmaceutical compositions of the present invention can be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), lozenges, dragees, capsules, pills, tablets (e.g., those targeted for buccal, sublingual, and systemic absorption), boluses, powders, granules, pastes for application to the tongue; (2) parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; (3) topical application, for example, as a cream, ointment, or a controlled-release patch or spray applied to the skin; (4) intravaginally or intrarectally, for example, as a pessary, cream or foam; (5) sublingually; (6) ocularly; (7) transdermally; (8) transmucosally; or (9) nasally. Additionally, compounds can be implanted into a patient or injected using a drug delivery system. See, for example, Urquhart, et al, Arm. Rev. Pharmacol. Toxicol. 24: 199-236 (1984); Lewis, ed. “Controlled Release of Pesticides and Pharmaceuticals” (Plenum Press, New York, 1981); U.S. Pat. No. 3,773,919; and U.S. Pat. No. 35 3,270,960. In some embodiments direct administration to a tumor and/or a body cavity, orifice, and/or tissue containing a tumor may be desired.
As used here, the term “pharmaceutically acceptable” refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
As used here, the term “pharmaceutically-acceptable carrier” means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid), or solvent encapsulating material, involved in carrying
or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically- acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, methylcellulose, ethyl cellulose, microcrystalline cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) lubricating agents, such as magnesium stearate, sodium lauryl sulfate and talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol (PEG); (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) pH buffered solutions; (21) polyesters, polycarbonates and/or polyanhydrides; (22) bulking agents, such as polypeptides and amino acids (23) serum component, such as serum albumin, HDL and LDL; (22) C2-C12 alcohols, such as ethanol; and (23) other non-toxic compatible substances employed in pharmaceutical formulations. Wetting agents, coloring agents, release agents, coating agents, sweetening agents, flavoring agents, perfuming agents, preservative and antioxidants can also be present in the formulation. The terms such as “excipient”, “carrier”, “pharmaceutically acceptable carrier” or the like are used interchangeably herein.
Methods of Treatment
Disclosed herein are methods of increasing T cell proliferation. In some embodiments, the method includes modifying a T cell to comprise an IL12p p40 subunit.
Also disclosed herein are methods of treating or preventing a cancer in a subject in need thereof. In some embodiments the method includes administering a modified T cell comprising an IL12p p40 subunit, as described herein. In some
embodiments the method including administering a therapeutically effective amount of modified T cells comprising an PA2b p40 subunit.
Also disclosed herein are methods of generating a population of modified T cells in a subject (e.g., a subject diagnosed with cancer and/or otherwise in need thereof). In some embodiments, the method includes administering to a subject a T cell modified to comprise an IIA2b p40 subunit. In some aspects, the population of modified T cells persists in the subject for a period of time following administration to the subject (e.g., at least one week, one month, two months, three months, four months, five months, six months, nine months, one year, two years, five years, etc.).
Further disclosed herein are methods of expanding a population of modified T cells in a subject (e.g., a subject diagnosed with cancer and/or a subject in need thereof). In some embodiments, the method includes administering to the subject a T cell modified to comprise an IL l 2b p40 subunit, where the administered modified T cell produces a population of progeny cells in the subject.
In some embodiment, the cells described herein, e.g. modified T cells are transplantable, e.g., modified T cells can be administered to a subject. In some embodiments, the subject who is administered modified T cells is the same subject from whom the pre-modified T cells was obtained (e.g. for autologous cell therapy).
In some embodiments, the subject is a different subject. In some embodiments, a subject is suffering from cancer, or is a normal subject. For example, the modified T cells for transplantation can be a form suitable for transplantation.
The method can further include administering the modified T cells to a subject in need thereof, e.g., a mammalian subject, e.g., a human subject. The source of the cells can be a mammal, preferably a human. The source or recipient of the cells can also be a non-human subject, e.g., an animal model. The term “mammal” includes organisms, which include mice, rats, cows, sheep, pigs, rabbits, goats, horses, monkeys, dogs, cats, and preferably humans. Likewise, transplantable cells can be obtained from any of these organisms, including a non-human transgenic organism.
A composition comprising modified T cells can be administered to a subject using an implantable device. Implantable devices and related technology are known in the art and are useful as delivery systems where a continuous, or timed-release delivery of compounds or compositions delineated herein is desired. Additionally, the
implantable device delivery system is useful for targeting specific points of compound or composition delivery (e.g., localized sites, organs). Negrin et al, Biomaterials, 22(6):563 (2001). Timed-release technology involving alternate delivery methods can also be used in this invention. For example, timed-release formulations based on polymer technologies, sustained-release techniques and encapsulation techniques (e.g., polymeric, liposomal) can also be used for delivery of the compounds and compositions delineated herein.
As used herein, the term “administer” refers to the placement of a composition into a subject by a method or route which results in at least partial localization of the composition at a desired site such that desired effect is produced. Routes of administration suitable for the methods of the invention include both local and systemic administration. Generally, local administration results in more of the administered modified T cells being delivered to a specific location as compared to the entire body of the subject, whereas, systemic administration results in delivery of the modified T cells to essentially the entire body of the subject.
In the context of administering modified T cells, the term “administering” also include transplantation of such cells in a subject. As used herein, the term “transplantation” refers to the process of implanting or transferring at least one cell to a subject. The term “transplantation” includes, e.g., autotransplantation (removal and transfer of cell(s) from one location on a patient to the same or another location on the same patient), allotransplantation (transplantation between members of the same species), and xenotransplantation (transplantations between members of different species). A skilled artisan is well aware of methods for implanting or transplantation of cells for treating cancer, which are amenable to the present invention.
Modified T cells or compositions comprising the same can be administered by any appropriate route known in the art including, but not limited to, oral or parenteral routes, including intravenous, intramuscular, subcutaneous, transdermal, airway (aerosol), pulmonary, nasal, rectal, and topical (including buccal and sublingual) administration.
Exemplary modes of administration include, but are not limited to, injection, infusion, instillation, inhalation, or ingestion. “Injection” includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intraventricular, intracapsular,
intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, sub capsular, subarachnoid, intraspinal, intracerebro spinal, and intrasternal injection and infusion. In preferred embodiments, the compositions are administered by intravenous infusion or injection.
As used herein, a “subject” means a human or animal. Usually the animal is a vertebrate such as a primate, rodent, domestic animal or game animal. Primates include chimpanzees, cynomologous monkeys, spider monkeys, and macaques, e.g., Rhesus. Rodents include mice, rats, woodchucks, ferrets, rabbits and hamsters. Domestic and game animals include cows, horses, pigs, deer, bison, buffalo, feline species, e.g., domestic cat, canine species, e.g., dog, fox, wolf, avian species, e.g., chicken, emu, ostrich, and fish, e.g., trout, catfish and salmon. Patient or subject includes any subset of the foregoing, e.g., all of the above, but excluding one or more groups or species such as humans, primates or rodents. In certain embodiments of the aspects described herein, the subject is a mammal, e.g., a primate, e.g., a human. The terms, “patient” and “subject” are used interchangeably herein. The terms, “patient” and “subject” are used interchangeably herein. A subject can be male or female.
Preferably, the subject is a mammal. The mammal can be a human, non human primate, mouse, rat, dog, cat, horse, or cow, but are not limited to these examples. In addition, the methods and compositions described herein can be used to treat domesticated animals and/or pets.
In some embodiments a subject is deemed “at risk” of having or developing cancer or recurrence of cancer. Whether a subject is at risk of having or developing cancer or having a recurrence of cancer is a determination that may be within the discretion of the skilled practitioner caring for the subject. Any suitable diagnostic test and/or criteria can be used. For example, a subject may be considered “at risk” of having or developing cancer if (i) the subject has a mutation, genetic polymorphism, gene or protein expression profile, and/or presence of particular substances in the blood, associated with increased risk of developing or having cancer relative to other members of the general population not having mutation or genetic polymorphism; (ii) the subject has one or more risk factors such as having a family history of cancer, having been exposed to a carcinogen or tumor-promoting agent or condition, e.g., asbestos, tobacco smoke, aflatoxin, radiation, chronic infection/inflammation, etc.,
advanced age; (iii) the subject has one or more symptoms of cancer, (iv) the subject has a medical condition that is known to increase the likelihood of cancer, etc.
As used herein, the type of cancer is not limited. The term “cancer” as used herein is defined as a hyperproliferation of cells whose unique trait — loss of normal controls — results in unregulated growth, lack of differentiation, local tissue invasion, and metastasis. With respect to the inventive methods, the cancer can be any cancer, including any of acute lymphocytic cancer, acute myeloid leukemia, adenocarcinoma, alveolar rhabdomyosarcoma, anal cancer, angiosarcoma, B cell lymphoma, basal cell carcinoma, bladder cancer, bone cancer, brain cancer, breast cancer, cancer of the anus, anal canal, or anorectum, cancer of the eye, cancer of the intrahepatic bile duct, cancer of the joints, cancer of the neck, gallbladder, or pleura, cancer of the nose, nasal cavity, or middle ear, cancer of the oral cavity, cancer of the vulva, chronic lymphocytic leukemia, chronic myeloid cancer, colon cancer, colorectal cancer, esophageal cancer, cervical cancer, endometrial cancer, fibrosarcoma, gastrointestinal carcinoid tumor, hematopoietic neoplasias, Hodgkin lymphoma, hypopharynx cancer, kidney cancer, larynx cancer, leukemia, liquid tumors, liver cancer, lung cancer, lymphoma, malignant mesothelioma, mastocytoma, melanoma, multiple myeloma, myeloma, nasopharynx cancer, non-Hodgkin lymphoma, ovarian cancer, pancreatic cancer, peritoneum, omentum, and mesentery cancer, pharynx cancer, prostate cancer, rectal cancer, renal cancer, sarcoma, skin cancer, small intestine cancer, soft tissue cancer, solid tumors, squamous cell carcinoma, stomach cancer, T cell lymphoma, testicular cancer, thymoma, thyroid cancer, ureter cancer, urinary bladder cancer, and uterine cancer. As used herein, the term “tumor” refers to an abnormal growth of cells or tissues of the malignant type, unless otherwise specifically indicated and does not include a benign type tissue.
As used herein, the term "treating" and "treatment" refers to administering to a subject an effective amount of modified T cells altered ex vivo according to the methods described herein so that the subject has a reduction in at least one symptom of the disease or an improvement in the disease, for example, beneficial or desired clinical results. For purposes of this invention, beneficial or desired clinical results include, but are not limited to, alleviation of one or more symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of
disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. Treating can refer to prolonging survival as compared to expected survival if not receiving treatment. Thus, one of skill in the art realizes that a treatment may improve the disease condition, but may not be a complete cure for the disease. As used herein, the term "treatment" includes prophylaxis. Alternatively, treatment is “effective” if the progression of a disease is reduced or halted. "Treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already diagnosed with a disorder associated with expression of a polynucleotide sequence, as well as those likely to develop such a disorder due to genetic susceptibility or other factors.
By “treatment,” “prevention” or “amelioration” of a disease or disorder is meant delaying or preventing the onset of such a disease or disorder, reversing, alleviating, ameliorating, inhibiting, slowing down or stopping the progression, aggravation or deterioration the progression or severity of a condition associated with such a disease or disorder. In one embodiment, the symptoms of a disease or disorder are alleviated by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%.
The dosage, administration schedule and method of administering the modified T cells are not limited. The dosage will depend upon a variety of factors including other treatment, the number of doses and the individual patient parameters including age, physical condition, size and weight. These are factors well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation. In some embodiments, a maximum tolerated dose may be used, that is, the highest safe and tolerable dose according to sound medical judgment. In some embodiments, a pharmaceutical composition comprising the modified T cells can be administered at a dosage of about 103to about 1010 cells/kg body weight, and in some embodiments, the dosage can be from about 105to about 106 cells/kg body weight, including all integer values (e.g., 104, 105, 106, 107,108, 109) within those ranges.
The dose used may be the maximal tolerated dose or a sub-therapeutic dose or any dose therebetween. In some embodiments modified T cells are administered in combination with one or more agents. In some embodiments, the modified T cells
and/or the one or more agents are administered according to a defined administration schedule. Multiple doses are contemplated. In some embodiments, when the modified T cells and one or more agents are administered in combination, a sub- therapeutic dosage of one or more of the agents may be used. A “sub-therapeutic dose” as used herein refers to a dosage which is less than that dosage which would produce a therapeutic result in the subject if administered in the absence of the other agent. In some aspects, a sub-therapeutic dose of an anticancer agent is one which would not produce a useful therapeutic result in the subject in the absence of the administration of the modified T cells described herein. Therapeutic doses of anticancer agents are well known in the field of medicine for the treatment of cancer.
As used herein, pharmaceutical compositions comprise one or more agents or compositions that have therapeutic utility, and a pharmaceutically acceptable carrier, e.g., a carrier that facilitates delivery of agents or compositions. Agents and pharmaceutical compositions disclosed herein may be administered by any suitable means such as orally, intranasally, subcutaneously, intramuscularly, intravenously, intra-arterially, parenterally, intraperitoneally, intrathecally, intratracheally, ocularly, sublingually, vaginally, rectally, dermally, or as an aerosol. Depending upon the type of condition (e.g., cancer) to be treated, compounds of the invention may, for example, be inhaled, ingested or administered by systemic routes. Thus, a variety of administration modes, or routes, are available. The particular mode selected will typically depend on factors such as the particular compound selected, the particular condition being treated and the dosage required for therapeutic efficacy. The methods described herein, generally speaking, may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces acceptable levels of efficacy without causing clinically unacceptable adverse effects. Preferred modes of administration are parenteral and oral routes. The term “parenteral” includes subcutaneous, intravenous, intramuscular, intraperitoneal, and intrasternal injection, or infusion techniques. In some embodiments, inhaled medications are of particular use because of the direct delivery to the lung, for example in lung cancer patients. Several types of metered dose inhalers are regularly used for administration by inhalation. These types of devices include metered dose inhalers (MDI), breath-actuated MDI, dry powder inhaler (DPI), spacer/holding
chambers in combination with MDI, and nebulizers. In some embodiments agents are delivered by pulmonary aerosol. Other appropriate routes will be apparent to one of ordinary skill in the art.
Toxicity and therapeutic efficacy of administration of compositions comprising modified T cells can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). Compositions comprising modified T cells that exhibit large therapeutic indices are preferred.
The amount of a composition comprising modified T cells can be tested using several well-established animal models.
In some embodiments, data obtained from the cell culture assays and in animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
The therapeutically effective dose of a composition comprising modified T cells can also be estimated initially from cell culture assays. Alternatively, the effects of any particular dosage can be monitored by a suitable bioassay.
With respect to duration and frequency of treatment, it is typical for skilled clinicians to monitor subjects in order to determine when the treatment is providing therapeutic benefit, and to determine whether to increase or decrease dosage, increase or decrease administration frequency, discontinue treatment, resume treatment or make other alteration to treatment regimen. The dosing schedule can vary from once a week to daily depending on a number of clinical factors. The desired dose can be administered at one time or divided into subdoses, e.g., 2-4 subdoses and administered over a period of time, e.g., at appropriate intervals through the day or other appropriate schedule. Such sub-doses can be administered as unit dosage forms. In some embodiments, administration is chronic, e.g., one or more doses daily over a period of weeks or months. Examples of dosing schedules are administration daily, twice daily, three times daily or four or more times daily over a period of 1 week, 2
weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months or more.
In another aspect of the invention, the methods provide use of an isolated population of modified T cells. In one embodiment of the invention, an isolated population of modified T cells as disclosed herein may be used for the production of a pharmaceutical composition, for the use in transplantation into subjects in need of treatment, e.g. a subject that has, or is at risk of developing cancer. Examples include subjects with melanoma or pancreatic cancer. In some embodiments, an isolated population of modified T cells as disclosed herein may be autologous and/or allogeneic. In some embodiments, the subject is a mammal, and in other embodiments the mammal is a human.
One embodiment of the invention relates to a method of treating cancer in a subject comprising administering an effective amount of a composition comprising modified T cells as disclosed herein to a subject with cancer. Other embodiments relate to a method of treating a tumor in a subject comprising administering an effective amount of a composition comprising modified T cells as disclosed herein to a subject with a tumor.
In some embodiments, the modified T cells as disclosed herein are administered to a subject having cancer in combination with a second therapeutic treatment (e.g., chemotherapy, radiation, immunosuppressive agents, such as cyclosporin, azathioprine, methotrexate, mycophenolate, and FK506, antibodies, or other immunoablative agents such as CAM PATH, anti-CD3 antibodies or other antibody therapies, cytotoxin, fludaribine, cyclosporin, FK506, rapamycin, mycophenolic acid, steroids, FR901228, cytokines, and/or irradiation).
In some embodiments, the modified T cells are administered to a patient in conjunction with (e.g., before, concurrently and/or following) bone marrow transplantation, T cell ablative therapy using either chemotherapy agents such as fludarabine, external-beam radiation therapy (XRT), cyclophosphamide, or antibodies such as OKT3 or CAMPATH. In another embodiment, the modified T cells are administered following B-cell ablative therapy such as agents that react with CD20, e.g., Rituxan. For example, in one embodiment, subjects may undergo standard treatment with high dose chemotherapy followed by peripheral blood stem cell
transplantation. In certain embodiments, following the transplant, subjects can receive an infusion of the expanded modified T cells. In an additional embodiment, expanded cells can be administered before and/or following surgery.
In the treatment of cancers or tumors the modified T cells may optionally be administered in conjunction with other, different, cytotoxic agents such as chemotherapeutic or antineoplastic compounds or radiation therapy useful in the treatment of the disorders or conditions described herein (e.g., chemotherapeutics or antineoplastic compounds). The other compounds may be administered prior to, concurrently and/or after administration of the modified T cells. As used herein, the word “concurrently” means sufficiently close in time to produce a combined effect (that is, concurrently may be simultaneously, or it may be two or more administrations occurring before or after each other)
As used herein, the phrase “radiation therapy” includes, but is not limited to, x-rays or gamma rays which are delivered from either an externally applied source such as a beam or by implantation of small radioactive sources.
Nonlimiting examples of suitable chemotherapeutic agents which may be administered with the modified T cells as described herein include daunomycin, cisplatin, verapamil, cytosine arabinoside, aminopterin, democolcine, tamoxifen, Actinomycin D, Alkylating agents (including, without limitation, nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas and triazenes): Uracil mustard, Chlormethine, Cyclophosphamide (Cytoxan®), Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Tri ethylene-melamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, and Temozolomide; Antimetabolites (including, without limitation, folic acid antagonists, pyrimidine analogs, purine analogs and adenosine deaminase inhibitors): Methotrexate, 5- Fluorouracil, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, Pentostatine, and Gemcitabine, Natural products and their derivatives (for example, vinca alkaloids, antitumor antibiotics, enzymes, lymphokines and epipodophyllotoxins): Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Ara-C, paclitaxel (paclitaxel is commercially available as Taxol®), Mithramycin, Deoxyco-formycin, Mitomycin-C, L- Asparaginase, Interferons (especially IFN-a), Etoposide, and Teniposide; Other
anti-proliferative cytotoxic agents are navelbene, CPT-11, anastrazole, letrazole, capecitabine, reloxafme, cyclophosphamide, ifosamide, and droloxafme. Additional anti-proliferative cytotoxic agents include, but are not limited to, melphalan, hexamethyl melamine, thiotepa, cytarabin, idatrexate, trimetrexate, dacarbazine, L- asparaginase, camptothecin, topotecan, bicalutamide, flutamide, leuprolide, pyridobenzoindole derivatives, interferons, and interleukins. Preferred classes of antiproliferative cytotoxic agents are the EGFR inhibitors, Her-2 inhibitors, CDK inhibitors, and Herceptin® (trastuzumab). (see, e.g., U.S. Pat. Nos. 6,537,988; 6,420,377). Such compounds may be given in accordance with techniques currently known for the administration thereof.
In some embodiments, the modified T cells as disclosed herein may be administered in any physiologically acceptable excipient, where the modified T cells may find an appropriate site for replication, proliferation, and/or engraftment. In some embodiments, the modified T cells as disclosed herein can be introduced by injection, catheter, or the like. In some embodiments, the modified T cells as disclosed herein can be frozen at liquid nitrogen temperatures and stored for long periods of time, being capable of use on thawing. If frozen, the modified T cells will usually be stored in a 10% DMSO, 50% FCS, 40% RPMI 1640 medium. Once thawed, the cells may be expanded by use of growth factors and/or feeder cells associated with culturing T cells.
In some embodiments, the modified T cells as disclosed herein can be supplied in the form of a pharmaceutical composition, comprising an isotonic excipient prepared under sufficiently sterile conditions for human administration. For general principles in medicinal formulation, the reader is referred to Cell Therapy: Stem Cell Transplantation, Gene Therapy, and Cellular Immunotherapy, by G. Morstyn & W. Sheridan eds, Cambridge University Press, 1996; and Hematopoietic Stem Cell Therapy, E. D. Ball, J. Lister & P. Law, Churchill Livingstone, 2000. Choice of the cellular excipient and any accompanying elements of the composition comprising the modified T cells as disclosed herein will be adapted in accordance with the route and device used for administration. In some embodiments, a composition comprising the modified T cells can also comprise or be accompanied with one or more other ingredients that facilitate the engraftment or functional
mobilization of the modified T cells. Suitable ingredients include matrix proteins that support or promote adhesion of the modified T cells, or complementary cell types. In another embodiment, the composition may comprise resorbable or biodegradable matrix scaffolds.
In some embodiments, the modified T cells can be administered and dosed in accordance with good medical practice, taking into account the clinical condition of the individual patient, the site and method of administration, scheduling of administration, patient age, sex, body weight and other factors known to medical practitioners. The pharmaceutically “effective amount” for purposes herein is thus determined by such considerations as are known in the art. The amount must be effective to achieve improvement, including but not limited to improved survival rate or more rapid recovery, or improvement or elimination of symptoms and other indicators as are selected as appropriate measures by those skilled in the art. Modified T cells can be administered to a subject at the following locations: clinic, clinical office, emergency department, hospital ward, intensive care unit, operating room, catheterization suites, and radiologic suites.
In other embodiments, the modified T cells are stored for later implantation/infusion. The modified T cells may be divided into more than one aliquot or unit such that a portion of the modified T cells are retained for later application while part is applied immediately to the subject. Moderate to long-term storage of all or part of the cells in a cell bank is also within the scope of this invention, as disclosed in U.S. Patent Publication No. 2003/0054331 and Patent Publication No. WO 03/024215, and is incorporated by reference in their entireties.
At the end of processing, the concentrated cells may be loaded into a delivery device, such as a syringe, for placement into the recipient by any means known to one of ordinary skill in the art.
Pharmaceutical compositions comprising effective amounts of modified T cells are also contemplated by the present invention. These compositions comprise an effective number of modified T cells, optionally, in combination with a pharmaceutically acceptable carrier, additive or excipient. Systemic administration of modified T cells to the subject may be preferred in certain indications, whereas direct
administration at the site of or in proximity a tumor may be preferred in other indications.
In some embodiments, modified T cells can optionally be packaged in a suitable container with written instructions for a desired purpose, such as the reconstitution or thawing (if frozen) of the modified T cells prior to administration to a subject.
One skilled in the art readily appreciates that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The details of the description and the examples herein are representative of certain embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Modifications therein and other uses will occur to those skilled in the art. These modifications are encompassed within the spirit of the invention. It will be readily apparent to a person skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention.
The articles “a” and “an” as used herein in the specification and in the claims, unless clearly indicated to the contrary, should be understood to include the plural referents. Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The invention includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The invention also includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process. Furthermore, it is to be understood that the invention provides all variations, combinations, and permutations in which one or more limitations, elements, clauses, descriptive terms, etc., from one or more of the listed claims is introduced into another claim dependent on the same base claim (or, as relevant, any other claim) unless otherwise indicated or unless it would be evident to one of ordinary skill in the art that a contradiction or inconsistency would arise. It is contemplated that all
embodiments described herein are applicable to all different aspects of the invention where appropriate. It is also contemplated that any of the embodiments or aspects can be freely combined with one or more other such embodiments or aspects whenever appropriate. Where elements are presented as lists, e.g., in Markush group or similar format, it is to be understood that each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It should be understood that, in general, where the invention, or aspects of the invention, is/are referred to as comprising particular elements, features, etc., certain embodiments of the invention or aspects of the invention consist, or consist essentially of, such elements, features, etc. For purposes of simplicity those embodiments have not in every case been specifically set forth in so many words herein. It should also be understood that any embodiment or aspect of the invention can be explicitly excluded from the claims, regardless of whether the specific exclusion is recited in the specification. For example, any one or more active agents, additives, ingredients, optional agents, types of organism, disorders, subjects, or combinations thereof, can be excluded.
Where the claims or description relate to a composition of matter, it is to be understood that methods of making or using the composition of matter according to any of the methods disclosed herein, and methods of using the composition of matter for any of the purposes disclosed herein are aspects of the invention, unless otherwise indicated or unless it would be evident to one of ordinary skill in the art that a contradiction or inconsistency would arise. Where the claims or description relate to a method, e.g., it is to be understood that methods of making compositions useful for performing the method, and products produced according to the method, are aspects of the invention, unless otherwise indicated or unless it would be evident to one of ordinary skill in the art that a contradiction or inconsistency would arise.
Where ranges are given herein, the invention includes embodiments in which the endpoints are included, embodiments in which both endpoints are excluded, and embodiments in which one endpoint is included and the other is excluded. It should be assumed that both endpoints are included unless indicated otherwise. Furthermore, it is to be understood that unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value or subrange within the stated ranges in
different embodiments of the invention, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise. It is also understood that where a series of numerical values is stated herein, the invention includes embodiments that relate analogously to any intervening value or range defined by any two values in the series, and that the lowest value may be taken as a minimum and the greatest value may be taken as a maximum. Numerical values, as used herein, include values expressed as percentages. For any embodiment of the invention in which a numerical value is prefaced by “about” or “approximately”, the invention includes an embodiment in which the exact value is recited. For any embodiment of the invention in which a numerical value is not prefaced by “about” or “approximately”, the invention includes an embodiment in which the value is prefaced by “about” or “approximately”.
As used herein “A and/or B”, where A and B are different claim terms, generally means at least one of A, B, or both A and B. For example, one sequence which is complementary to and/or hybridizes to another sequence includes (i) one sequence which is complementary to the other sequence even though the one sequence may not necessarily hybridize to the other sequence under all conditions, (ii) one sequence which hybridizes to the other sequence even if the one sequence is not perfectly complementary to the other sequence, and (iii) sequences which are both complementary to and hybridize to the other sequence.
“Approximately” or “about” generally includes numbers that fall within a range of 1% or in some embodiments within a range of 5% of a number or in some embodiments within a range of 10% of a number in either direction (greater than or less than the number) unless otherwise stated or otherwise evident from the context (except where such number would impermissibly exceed 100% of a possible value).
It should be understood that, unless clearly indicated to the contrary, in any methods claimed herein that include more than one act, the order of the acts of the method is not necessarily limited to the order in which the acts of the method are recited, but the invention includes embodiments in which the order is so limited. It should also be understood that unless otherwise indicated or evident from the context, any product or composition described herein may be considered “isolated”.
As used herein the term "comprising" or "comprises" is used in reference to compositions, methods, and respective component(s) thereof, that are essential to the invention, yet open to the inclusion of unspecified elements, whether essential or not. As used herein the term "consisting essentially of' refers to those elements required for a given embodiment. The term permits the presence of additional elements that do not materially affect the basic and novel or functional characteristic(s) of that embodiment of the invention.
The term "consisting of' refers to compositions, methods, and respective components thereof as described herein, which are exclusive of any element not recited in that description of the embodiment.
* * *
EXEMPLIFICATION:
Introduction
T cells are a main focus for cancer immunotherapies due to their potent anti tumor activity. While most endogenous T cells in cancer patients are either non- responsive or dysfunctional [1], they can be armed via genetic engineering with a tumor-targeting T cell receptor (TCR) or a chimeric antigen receptor (CAR) [2] Both TCR and CAR-engineered T cells promote substantial objective clinical responses in synovial carcinoma [3] and B cell lymphoid malignancies [4], respectively. In particular, CAR-expressing T cells expand in vivo in patients with B cell leukemia and can persist up to 24 months post infusion [5] In contrast, T cell expansion and persistence within the TME is usually hindered in solid tumors by multiple factors such as checkpoint inhibition [6] and metabolic starvation [1]
T cell proliferation requires optimal T cell activation, which integrates signals downstream of the T cell receptor (TCR)/CD3 complex, engagement of costimulatory molecules and cytokines [7] CAR-based engineering provides the first two factors, while TCR-based engineering remains challenging in providing adequate costimulation [7] However, for both TCR and CAR engineering strategies, the cytokine component remains a significant limiting factor as the only secreted cytokine by engineered T cells is IL2, which may support the activation and expansion of regulatory T cells (Tregs) [8] Additional engineering of CAR T cells with common g
chain cytokines such as IL15 is effective in supporting their proliferation and effector function, while the effects on Tregs are limited [9, 10] However, cytokine engineering can lead to side effects as they are constitutively produced and their receptor being expressed by most T cells and natural killer (NK) cells, requiring the inclusion of safety switches to contain potential toxic effects [11-13] Thus, the development of inducible and selective engineering processes supporting T cell expansion and survival within the TME remain critical in adoptive T cell therapies in solid tumors.
While most of the studies on cytokines supporting T cell immunotherapies focus on STAT5 inducing cytokines, recent studies showed that STAT3 signaling enhances CAR T cell effector function in pre-clinical models [14] and it is associated with better clinical outcome in patients with chronic lymphocytic leukemia [15] IL23 is one of the STAT3 activating cytokines that consists of IL23a pl9 and IL l 2b p40 subunits [16], both expressed by activated macrophages and dendritic cells [17-18] The IL23 receptor (IL23R) is commonly expressed in Thl7 cells [19] and IL23 promotes Thl7 cell differentiation and proliferation [17, 91, 20] Activation-induced expression of the IL23R and IL23a pl9 subunit was found in T cells, which allowed for the coupling of the release and activity of IL23 with T cell activation by supplementing the IIA2b p40 subunit to T cells. p40-expressing T (p40-Td) cells produce IL23 upon T cell activation, which drives T cell proliferation and survival. Incorporating p40 in CAR- or TCR-engineered T cells enhanced their antitumor activity in xenograft and syngeneic mouse models. Furthermore, IL23 produced by p40-Td cells functions predominantly through an autocrine mechanism with limited effects on bystander cells. Taken together, this approach provides robust and selective proliferative signaling to adoptively transfer tumor-specific T cells within the TME.
Results
TCR stimulation upregulates the expression of IL23R in T cells.
First evaluated was whether the IL23R is expressed in T cells expanded ex vivo following procedures used to generate CAR T cells for clinical use and that expand T cells phenotypically resembling memory T cells [21] (here collectively called ex-TM). While ex-TM expanding ex vivo at day 10 - 12 express low levels of
IL23R, TCR stimulation upregulates IL23R expression at both mRNA and protein levels (FIGS. 1A-1B). IL23R expression in ex-TM is functional because recombinant IL23 supports the expansion of activated ex-TM, as previously observed in IL23R+ Thl7 cells [22], while ex-TM are irresponsive to IL23 in the absence of TCR stimulation (FIG. 1C). Furthermore, ex-TM responding to IL23 was not polarized to Thl7 cells as they show similar CD4 and CD8 ratio as untreated T cells (FIG. ID), retain a type I cytokine production profile (FIG. IE), and show similar T-bet/RORyT expression [23] (FIG. IF). This selective activity of IL23 without skewing towards a pathogenic Thl7 subset prompted us to explore whether the IL23/IL23R axis can be exploited to support the expansion of activated T cells within the TME.
Functional engineering of the IL23/IL23R axis in T cells.
Unexpectedly, it was observed that ex-TM upregulates the IL23a pl9 subunit upon TCR stimulation, but not the IL12b p40 subunit (FIG. 1G). The observed inducible expression of both IL23R and IL23a pl9 subunit in CX-TM in response to TCR stimulation offers the unique opportunity to genetically engineer these cells with the IL12b p40 subunit to produce and utilize IL23 upon TCR stimulation. The p40 subunit has been supplemented to ex-TM via gamma retroviral transduction to generate p40-expressing T (p40-Td) cells (FIG. 7A). p40-Td cells, but not empty vector-transduced T (Ctrl) cells, secrete IL23 upon TCR stimulation (FIG. 1H). Of note, p40-Td cells released limited amount of IL12 (< 50 pg/mL), a cytokine that shares the p40 subunit with IL23 [20] (FIG. 1H). In the absence of TCR stimulation, p40-Td and Ctrl cells showed comparable phenotypic characteristics and expansion in culture (FIGS. 7B-7E). In contrast, p40-Td cells showed superior expansion upon TCR activation as compared to Ctrl cells (FIG. IE). This effect can be attributed to both increased cell division (FIGS. 8A-8B) and reduced apoptosis (FIG. 8C). IL23- mediated responses of p40-Td cells requires the endogenous IL23a subunit because knockdown of the IL23A gene abolishes both IL23 production (FIG. 1 J) and IL23- mediated T cell expansion (FIG. IK) of p40-Td cells.
Previous studies showed elevated IL23A mRNA levels in tumor biopsies, suggesting the potential role of IL23 in tumor progression, especially in colorectal carcinoma (CRC) [24, 25] However, as a heterodimeric protein, both IL23a and
IL l 2b subunits must be present in the same cell to produce and release IL23. Analysis of RN A- sequencing data from The Cancer Genome Atlas (TCGA) showed that while the IL23A transcript is upregulated in many tumor specimens, the IL12B transcript is barely detectable in both tumor and normal tissue specimens (FIG. 1L), predicting the absence of IL23 within the TME. The expression of the IL23 subunits was also measured at both mRNA and protein levels with qPCR and ELISA, respectively in 18 tumor specimens (CRC, pancreatic ductal adenocarcinoma (PD AC) and breast cancer (BC)). While IL23A gene is upregulated in CRC tumor specimens, IL12B was not expressed (FIG. 1M) and IL23 protein was absent in most of the supernatants obtained from CRC specimens (FIG. IN). Therefore, IL23 p40 engineering of T cells may support T cell expansion in a TCR activation dependent manner within the TME that is deprived of IL23.
Transcriptome analysis of activated p40-Td cells reveals enriched STAT3 and hypoxia gene signature.
RNA-Seq analysis was performed to define the molecular pathways involved in p40-Td cells. Ctrl cells and p40-Td cells shared similar gene expression profile in the absence of TCR stimulation (FIG. 2A). In contrast, after TCR activation, p40-Td cells showed a different molecular signature as compared to Ctrl cells (FIGS. 2A-2C), indicating the requirement of TCR stimulation to fully exploit the effects of the engineered IL23/IL23R axis in CX-TM. Specifically, gene set enrichment analysis (GSEA) showed a significant enrichment of STAT3 upregulated genes in activated p40-Td cells and STAT3 downregulated genes in Ctrl cells (FIG. 2D), suggesting an elevated STAT3 activity in p40-Td cells. The molecular signature was validated by detecting increased STAT3 phosphorylation in activated p40-Td cells (FIG. 2E), and differential expression of STAT3 regulated genes (SOX2, SOCS3, CEBPD, ABCAl, IFIT1, IFIT3, USP18 and CDKN2B) (FIG. 2F). Furthermore, an enrichment of genes within the hypoxia hallmark gene set was observed in TCR stimulated p40-Td cells as compared to Ctrl cells (FIG. 2G) and mRNA upregulation of hypoxia-inducible factors (HIFs) and other HIF target genes was also observed (FIG. 2H). Overall, these data highlight the activation of the STAT3 pathway upon TCR activation in p40-Td cells, indicating a dominant role of IL23 signaling in these cells.
p40 expression enhances the anti-tumor activity of CAR T cells in xenograft models of solid tumors.
Whether IL23 p40 expression in CAR T cells improves their antitumor activity was assessed. p40 was expressed in CAR T cells (CAR.p40-Td) targeting the GD2 antigen expressed in neuroblastoma (NB) (FIG. 9A). CAR.p40-Td cells showed robust expansion (FIG. 9B) and reduced apoptosis (FIG. 9C) when stimulated in vitro with an anti-idiotype antibody that crosslinks the CAR [24], as compared to control CAR T cells (CAR. Ctrl cells). IL23 was only detected in activated CAR.p40-Td cells, while IL2 secretion remained unchanged (FIG. 9D). The anti-tumor effects of CAR T cells in vitro was assessed using repetitive tumor co-culture assays in which human NB cell lines (LAN-1 or CHLA-255) were used at high tumor to T cell ratio (FIG.
9E). In this stress culture condition test, CAR. Ctrl cells failed to control tumor growth after the first/second round of co-culture, while CAR.p40-Td cells remain effective (FIGS. 3A-3B). In parallel, the number of CAR. Ctrl cells gradually reduced after each round of co-culture, while CAR.p40-Td cells persisted (FIGS. 3C-3D). In addition to enhanced proliferation, the CAR.p40-Td cells showed superior effector functions at individual cell level. Specifically, CAR.p40-Td cells expressed higher level (percentage and MFI) of the lytic enzyme granzyme B (FIG. 3E) and reduced expression of the exhaustion markers PD1 and CD 101 [27] (FIG. 3F), as compared to CAR. Ctrl cells. In addition, after repeated stimulation, CAR. Ctrl cells underwent progressive reduction of T cells producing IFNy and TNFa, an indicator of functional exhaustion [28], while CAR.p40-Td cells continued to produce IFNy and TNFa (FIG. 3G). In a metastatic NB model in NOD/SCID/IL-2RnuU (NSG) mice, treated with suboptimal doses (2 x 106 cells) of CAR T cells, CAR.p40-Td cells promoted enhanced tumor control and improved survival as compared to CAR. Ctrl cells (FIGS. 3H-3K). Consistently, CAR.p40-Td cells showed superior initial expansion (day 10) in vivo in peripheral blood, spleen and liver (FIG. 3L), and prolonged persistence in the same organs at the time of euthanasia (FIG. 3M). When a higher dose (4 x 106 cells) of CAR T cells was used in tumor-bearing mice, both CAR. Ctrl cells and CAR.p40-Td cells promoted tumor regression (FIGS. 3N-3P), but only the mice receiving CAR.p40-Td cells were protected from tumor re-challenge 4 weeks after T
cell treatment (FIGS. 3N-3P). The enhanced anti-tumor activity of CAR.p40-Td cells was confirmed in a pancreatic ductal adenocarcinoma (PD AC) model using CAR T cells targeting the B7-H3 antigen [29] CAR.p40-Td cells showed superior anti-tumor effects and better persistence in stressed coculture condition against the human PD AC cell line BXPC-3 compared to CAR. Ctrl cells (FIGS. 4A-4B). Furthermore, in an orthotopic PD AC model using the BXPC-3 cell line that constitutively express high level of PD-L1 and is more resistant to CAR T cell effects [29], CAR.p40-Td cells showed superior anti-tumor effects and better persistence when compared to CAR. Ctrl cells (FIGS. 4C-4G). Therefore, p40 engineering of CAR T cells promotes anti-tumor activity sustaining T cell persistence and expansion.
Incorporation of p40 in murine T cell promotes local effects of IL23 in syngeneic tumor models of melanoma and pancreatic cancer.
To evaluate the effects of IL23 in immune replete mice, syngeneic tumor models were implemented. It was first confirmed that IL23R , IL23A , but not IL12B genes are inducible in ex vivo activated murine T cells that resemble human ex-TM generated for adoptive T cell transfer (FIGS. 5A-5B). Recapitulating the observation in human ex-TM, gene transfer of the murine IL12B in murine T cells resulted in the activation inducible IL23 secretion (FIG. 5C), and enhanced T cell expansion in vitro upon TCR stimulation (FIG. 5D). The anti-tumor effects of murine T cells expressing the murine p40 subunit were tested using the B 16-OVA melanoma mouse model and adoptive transfer of ex vivo expanded OT-1 T cells (FIG. 5E). When B16-OVA bearing mice were treated with suboptimal doses (1 x 106 cells/mouse) of OT1 T cells, OT1 T cells engineered to express p40 (OTl-mp40-Td cells) had superior tumor control as compared to OT1 T cells transduced with the empty vector (OT1-EV) (FIG. 5F (left)). Treatment with a higher dose (2 xlO6 cells/mouse) of OTl-mp40-Td showed sustained tumor control up to 30 days post tumor inoculation (FIG. 5F (right)). Notably, IL23 was only detected in the supernatant obtained from the tumor, but not in the serum of mice treated with OTl-mp40-Td cells (FIG. 5G). Correspondingly, in mice infused with OTl-mp40-Td cells, higher percentage of CD8+ OT1 T cells was observed within the tumor, but not in the blood, spleen and tumor draining lymph nodes (dLN) where the frequency of OT-1 T cells was similar
to mice receiving control OT1-EV T cells (FIG. 5H). Furthermore, no alteration in the composition of CD4 and CD8 T cells, B cells, NK cells and myeloid cells was observed in the blood, spleen, tumor and draining lymph nodes (FIG. 51). To further validate the approach using CAR T cells, a previously established syngeneic PD AC model and B7-H3-specific CAR-T cells was used [29] (FIG. 5J). Specifically, the KPC PD AC cell line expressing murine B7-H3 was orthotopically engrafted in C57BL/6 mice. Upon engraftment, mice were treated with murine T cells expressing the B7-H3-specific CAR co-expressing either an empty vector (B7-H3.CAR.EV) or the murine p40 subunit (B7-H3.CAR.mp40-Td). Mice treated with B7- H3.CAR.mp40-Td cells showed significantly better tumor control as compared to mice treated with B7-H3.CAR.EV cells (FIG. 5K). Collectively, it was demonstrated that p40 engineering in murine T cells expressing either a tumor specific TCR or CAR exert a local effect that enhances their anti-tumor activity without disturbance of global immune composition.
Engineered IL23 functions predominantly through an autocrine mode of action.
To better characterize the mode of action of IL23 in p40-expressing T cells, in vitro p40-Td cells, which are tagged with a truncated form of NGFR (NGFR+) [30], were mixed with control T cells tagged with a truncated form of CD 19 (ACD19-Td) [31] at 1:1 ratio and the mixed cells were stimulated with aCD3 and aCD28 Abs (FIG. 6A). Despite sharing the same culture media containing IL23 and expressing comparable levels of IL23R (FIG. 6B), p40-Td cells expanded more than ACD19-Td cells (FIGS. 6C-6D). Similarly, after multiple-round coculture assays with mixed CAR.p40-Td and control CAR.ACD19-Td cells, CAR.p40-Td cells preferentially expanded in response to tumor cells as compared to control CAR T cells (FIGS. 6E- 6F). To further study the self-beneficial effects of IL23 in p40-Td cells, IL23 produced by p40-Td cells was evaluated to determine if it preferentially binds with the IL23R expressed by p40-Td cells rather than the IL23R expressed by bystander cells. A p40-GFP fusion protein was generated that allows for the tracking of the location of IL23 (pl9-p40-GFP heterodimers) produced by T cells (FIG. 6G). p40- GFP -transduced (p40-GFP-Td) T cells were cocultured with CD19-tagged control T cells and measured the cell surface binding of the p40-GFP fusion protein using an
anti-GFP antibody conjugated to a far-red fluorochrome to discriminate true extracellular binding of the p40-GFP protein from the GFP signal within the cells (FIG. 6H). Upon TCR stimulation, both flow cytometry (FIG. 61) and confocal microscopy (FIG. 6J) showed abundant GFP surface binding on p40-GFP-Td cells, but not on ACD19-Td cells, even if the pl9-p40-GFP heterodimers can be readily detected in the culture media (FIG. 6G). These data confirm the preferential binding of IL23 to T cells that are producing IL23. One possible explanation for the IL23 preferential binding to IL23 -producing T cells is that IL23 is captured by IL23R in p40-Td cells before its diffusion. To test this hypothesis, a soluble recombinant human IL23R (rhIL23R) was used that binds IL23 preventing its engagement with the IL23R expressed by T cells (FIG. 10). It was found that even when IL23 proteins in diffusion were fully sequestered, the surface binding of p40-GFP to p40-Td cells remain unchanged as measured by both flow cytometry (FIG. 6K) and confocal microscopy (FIG. 6L). In addition, rhIL23R did not hamper IL23-mediated expansion of p40-Td cells (FIG. 6M), suggesting that the free IL23 does not contribute to the binding nor to the function of IL23 in p40-Td cells. Collectively, these data showed an autocrine mode of action of IL23 that has limited effects on bystander cells.
Discussion
In this study, it is demonstrated that providing the p40 subunit of IL23 to tumor-specific T cells is sufficient to cause the production and release of IL23. Furthermore, IL23 exerts its function exclusively through activated T cells because both the IL23 production and IL23R expression occur upon T cell activation. This tightly regulated IL23/IL23R engineered pathway is further controlled by an autocrine mode of action of the secreted IL23 that prevents cytokine usage by other bystander immune cells.
The role of IL23 in tumor cell growth remains controversial. Studies showed that low amounts of endogenous IL23 produced by either tumor associated macrophages, dendritic cells or tumor cells may promote inflammation favoring early tumor initiation and progression [19, 24, 25, 32] IL23 was also reported to promote metastasis in some CRC models [33] On the contrary, high levels of IL23, obtained either by IL23 -engineered tumor cells or administration of rIL23, caused anti-tumor
effects [34, 35] The data in multiple mouse models demonstrated the anti-tumor benefit of IL23, when this cytokine is produced by engineered tumor-specific T cells, while exhibiting no obvious side effects. Furthermore, it was observed that IL23 by itself is not sufficient to promote the differentiation of ex vivo generated tumor- specific T cells into IL17 producing cells, the main culprit for promoting carcinogenesis in IL23 sensitive tumors, such as CRC [25]
The unexpected observation was made that the IL23A pl9 gene, but not the IL12B p40 gene, is expressed in ex vivo generated tumor-specific T cells when these cells are activated either via engagement of the endogenous TCR or engagement of an inserted CAR. Furthermore, the observed activation-dependent pl9 expression is conserved in both murine and human T cells, and especially in murine T cells where pl9 expression is upregulated by more than 10000-fold upon activation. Notably, pl9 is sufficiently expressed to allow functional production and release of IL23 if the p40 subunit is provided. It is generally believed that no specific functions have been attributed to the single pl9 subunit. It is generally accepted that IL23 in its heterodimer form is assembled intracellularly and that pl9 is not secreted as an independent protein nor in association with proteins other than p40 [16, 36]
However, one study showed that human gastric carcinoma cells can secret pl9 in the absence of p40 subunit [37], which implies that the subunit may have IL23 independent functions. While the data suggest that IL23A knockdown does not cause detrimental effects in T cells, a more exhaustive assessment of the function pl9 in T cells is warranted.
The p40 engineering proposed has multiple potential advantages. While a milieu of cytokines supporting T cell survival and proliferation is critical to obtain anti-tumor effects after T cell adoptive therapies, the clinical experience demonstrates that toxic effects secondary to systemic and uncontrolled cytokine spread occur. The proposed p40-enginiering restricts cytokine spread because IL23 is released exclusively upon T cell activation within the TME. In fact, even if the p40 subunit is constitutively expressed in engineered T cells, IL23 is only assembled when the pl9 subunit is upregulated in response to T cell activation. Upon secretion within the TME, c-chain cytokines can be used by a variety of immune cells that express y - chain receptor, which either amplify or attenuate T cell-mediated immune responses
[38, 39] In contrast, IL23R expression is much more restricted and T cells releasing IL23 express high levels of IL23R. This scenario was previously modeled in the context of IL2 and regulatory T cells, showing that it favors the preferential capture of the cytokine by its producing cells and limits diffusion and bystander effects [40, 41] Indeed, IL23 released by p40-enginiered T cells is preferentially bound to the IL23R expressed by the same cells. This model for IL23 was supported by the data showing that soluble IL23R sequestering soluble IL23 did not reduce its binding and activity in p40-Td cells. Therefore, this autocrine mode of action of IL23 further improves the specificity and safety of p40-engineering in tumor specific T cells.
The generation of autologous cellular T cell products in cancer patients has the caveats that T cells may be functionally impaired due to age, specific disease and previous therapy the patient may have received. It was recently shown that in patients with chronic lymphocytic leukemia, which is characterized by the presence of dysfunctional T cells, the activation of the STAT3 signaling pathways correlated with better performance of CAR T cells generated ex vivo. The data support the beneficial role of STAT3 associated pathways, which are induced by IL23 through p40- engineering. Downstream of STAT3 signaling, an enrichment of hypoxia related genes in p40-Td cells was also observed. It is speculated that this effect is possibly due to the cooperative transactivation of STAT3 and HIFs transcription factor [42,
43] Furthermore, this molecular profile resembles the previously described hypoxia- signature in effector-memory T cells that likely contributes to the proliferative and anti-apoptotic functions of p40 [21]
In summary, a novel strategy is described to incorporate a highly regulated cytokine signaling into tumor-specific T cells that improves their efficacy. This approach has significant translational potential since it can be used for both CAR- and TCR-engineered T cells because both TCR and CAR activation allows upregulation of the IL23R and pl9 subunits and the endogenous pl9 subunit can be coupled with the ectopically expressed p40 subunit.
Methods
Cell Lines
The CHLA-255 neuroblastoma cell line was provided by L.S. Metelitsa of Baylor College of Medicine [44] and the LAN-1 cell line was obtained from M. Brenner at Baylor College of Medicine [45] Human PD AC cell line BXPC-3 was purchased from American Type Culture Collection (ATCC). Tumor cell lines were transduced with eGFP or firefly luciferase (Ffluc) for coculture and mouse experiments, respectively as previously described [46] Human tumor cell lines in this study (LAN-1, CHLA-255, BXPC-3) were maintained in complete RPMI medium (500mL RPMI- 1640 (Gibco), 10% FBS (Germini), 2 mM GlutaMAX (Gibco), 100 unit/mL of Penicillin and 100 pg/mL of streptomycin (Gibco)). Mouse melanoma B16-OVA was provided by Benjamin Vincent at University of North Carolina at Chapel Hill and was maintained in complete RPMI medium with addition of IOOmM b-mercaptoethanol (Fisher) and 500ug/mL G418 (Gibco) to maintain OVA expression. Mouse PD AC cell line KPC-mB7-H3 was established and described previously [29] and maintained in complete RPMI media. All cell lines were routinely tested for mycoplasma and for surface expression of target antigens.
Plasmid construction and retrovirus production.
The full-length human IL12B (accession number NM 002187.2) and murine IL12B (accession number NM_001303244.1) genes were amplified by PCR from cDNA clone purchased from Origene, and cloned into the retroviral vector SFG. Human IL12B were then subcloned into SFG vector containing the internal ribosomal entry site (IRES) and truncated NGFR selectable marker (p40(i)NGFR, FIG. 7A). As control, an empty vector containing the IRES and NGFR gene (Ctrl(i)NGFR) was used. The shRNA construct for IL23A gene was purchased from Origene (HuSH- 29™) and the promoter and shRNA sequence were amplified by PCR and cloned into SFG vector following a reverse (3’ to 5’) orientation. The p40-GFP fusion protein was generated by fusing the coding region of IL12B (1-328 amino acids) with the GFP gene by fusion PCR, and cloned into the SFG(I)NGFR. The CAR constructs used in this study were described previously [47]
Retroviral supernatants used for the transduction were prepared as previously described [48] To transduced human T cells, retrovirus with RDl 14 envelope was
used. For murine T cells transduction, retrovirus was generated using packaging vector encoding Eco envelope protein.
Transduction and expansion of human T cells.
Buffy coats from healthy donors were purchased from the Gulf Coast Regional Blood Center, Houston, TX. Peripheral blood mononuclear cells (PBMCs) isolated with Lymphoprep density separation (Fresenius Kabi Norge) were activated on plates coated with 1 pg/mL CD3 (Miltenyi Biotec) and 1 pg/mL CD28 (BD Biosciences) agonistic mAbs. On day 2, T lymphocytes were transduced with retroviral supernatants using retronectin-coated plates (Takara Bio Inc.). On day 4, transduced T cells were collected from retronectin plate and expanded in complete T cell medium (45% RPMI-1640 and 45% Click’s medium (Irvine Scientific), 10% FBS (Hyclone), 2 mM GlutaMAX, 100 unit/mL of Penicillin and 100 pg/mL of streptomycin) with IL-7 (10 ng/mL; PeproTech) and IL-15 (5 ng/mL; PeproTech), changing medium every 2 - 3 days [49] On day 10 - 14 days post transduction, cells are collected for in vitro and in vivo experiments. T cells were cultured in IL-7/IL-15 depleted medium for one days prior to being used in in vitro assays.
Preparation of ex vivo expanded murine T cells.
Murine T cells were isolated using Mojosort T cell isolation kit (Biolegend) from splenocytes obtained from C57BL/6J or C57BL/6-Tg(TcraTcrb)l lOOMjb/J (OT- 1) mice acquired from The Jackson Laboratory or in-house breeding. T cells were then stimulated on plates coated with 1 pg/mL mCD3 (eBioscience) and 1 pg/mL mCD28 mAbs (eBioscience) for 48 hours. Activated murine T lymphocytes were transduced with retroviral supernatants using retronectin-coated plates with the same protocol used to transduce human T cells. After removal from the retronectin plates, T cells were expanded in complete medium (RPMI-1640 (Gibco), 10% FBS (Hyclone), 2mM GlutaMAX, 100 pM b-mercaptoethanol, 100 unit/mL of Penicillin and 100 pg/mL of streptomycin) with IL-7 (10 ng/mL) and IL-15 (5 ng/mL) changing medium every 2 days. On day 5, T cells were collected and used for subsequent assays.
Quantitative real-time PCR.
RNA was extracted from cells with RNeasy Plus Kit (Qiagen), quantified using Nanodrop or Qubit and reverse-transcribed into cDNA using Superscript VILO (Thermo). Quantitative real-time PCR was performed using QuantStudio 6 Flex real time PCR system (Thermo). Taqman system was used in most assays except for the validation of RNA-Seq analysis (STAT3 regulated and hypoxia pathway genes), which used the SYBR Green system. For comparison of gene expression in human T cells, 18S RNA was used as housekeeping gene for normalization. For assays in mouse T cells, CD3E was used as housekeeping gene for normalization. For assays in patient specimens, absolute quantification of copies was conducted using standard curved generated with plasmid containing IL23A or IL12B cDNA.
The Taqman primers for the following genes were purchased from Applied Biosystem: human IL23A (assay ID: Hs00372324_ml) human IL12B (assay ID: HsOlOl 1518_ml) human 18S RNA (assay ID: Hs03003631_gl) human IL23R (assay ID: Hs00332759_ml) human TBX21 (assay ID: Hs00894392_ml) human RORC (assay ID: HsO 1076112_ml) murine IL23A (assay ID: Mm00518984_ml) murine IL12B (assay ID: Mm01288989_ml) murine CD3E (assay ID: MmOl 179194 ml) murine IL23R (assay ID: Mm00519943_ml)
The SYBR Green primers for the following genes were purchased from Sigma:
18S F: AACCCGTTGAACCCCATT (SEQ ID NO: 1);
R: CCATCCAATCGGTAGTAGCG (SEQ ID NO: 2);
SOX2 F: AT AAT AAC AATC ATCGGCGG (SEQ ID NO: 3);
R: AAAAAGAGAGAGGC AAACTG (SEQ ID NO: 4);
SOCS3 F: CCTATTACATCTACTCCGGG (SEQ ID NO: 5);
R: ACTTTCTCATAGGAGTCCAG (SEQ ID NO: 6);
CEBPD F: CAGACTTTTCAGACAAACCC (SEQ ID NO: 7);
R: TTTCGATTTCAAATGCTGC (SEQ ID NO: 8);
ABCA1 F: GT GTTTCT GGAT GAACCC (SEQ ID NO: 9);
R: TTCCATTGACCATGATTGC (SEQ ID NO: 10);
IFIT1 F: CTGCCTAATTTACAGCAACC (SEQ ID NO: 11);
R: TGATCCAAGACTCTGTTTTC (SEQ ID NO: 12); IFIT3 F: AT GAGT GAGGTC ACC AAG (SEQ ID NO: 13);
R: CCTTGAAGTTCCAGGTG (SEQ ID NO: 14);
USP18 F: TGGTTTACACAACATTGGAC (SEQ ID NO: 15);
R: ATCCTCTTCAATATCCTGGTG (SEQ ID NO: 16); CDKN2B F: GACT AGT GGAGAAGGT GC (SEQ ID NO: 17);
R: TCATCATGACCTGGATCG (SEQ ID NO: 18);
HIF1A F: AAAATCTC ATCC AAGAAGCC (SEQ ID NO: 19);
R: AATGTTCCAATTCCTACTGC (SEQ ID NO: 20); EPAS1 F : C AGAATC AC AGAACTGATTGG (SEQ ID NO : 21 );
R: TGACTCTTGGTCATGTTCTC (SEQ ID NO: 22); BNIP3L F: AGGC ATCT AT ATTGGAAAGC (SEQ ID NO: 23);
R: GCTTACAATGGTCTCAAGTT (SEQ ID NO: 24); PDK1 F: ATGATGTCATTCCCACAATG (SEQ ID NO: 25);
R: AAG AGT GCTGATTGAGT AAC (SEQ ID NO: 26); DDIT3 F: CTTTTCCAGACTGATCCAAC (SEQ ID NO: 27);
R: GATTCTTCCTCTTCATTTCCAG (SEQ ID NO: 28); DDIT4 F : AATGT AAGAGT AGGAAGGGG (SEQ ID NO : 29);
R: AC AGTTCT AGAT GG AAG ACC (SEQ ID NO: 30); EGLN1 F: CCCAAATTTGATAGACTGCTG (SEQ ID NO: 31);
R: ACACCTTTTTCACCTGTTAG (SEQ ID NO: 32); EGLN3 F: ATC ATTC AT AGC AGAT GT GG (SEQ ID NO: 33); and R: AT ATCTGGTTGCGT AAGAGG (SEQ ID NO: 34);
Immunoblotting analysis.
Cellular protein was extracted from cells using RIPA buffer (Thermo) supplemented with proteinase and phosphatase inhibitor (Thermo). Same amount of protein was separated on pre-cast 4-15% gradient gels (BioRad) by SDS-PAGE and transferred to PVDF membranes (BioRad). The membranes were blocked with 5% Milk in TBS-5% Tween buffer and probed with primary antibodies at 4 degree
overnight. Then, the membranes were washed and incubated with secondary antibodies conjugated to HRP. The following primary and secondary antibodies were used: anti-IL23R (Novus Biological 1:1000 Dilution), anti-GAPDH (clone 6C5, Santa Cruz, 1:1000 Dilution), anti-phospho-STAT3(Tyr705) (clone D3A7, Cell Signaling Technology, 1:1000 dilution), anti-phospho-STAT3(Ser727) (clone 6E4, Cell Signaling Technology, 1:1000 Dilution), anti-STAT3 (clone D3Z2G, Cell Signaling Technology, 1:1000 Dilution) and hhΐί^ϋ3z (clone 6B10.2, Santa Cruz, 1:1000 Dilution). Blot images were acquired with ChemiDoc MP system (BioRad) and the densitometry was calculated by Image Lab software (Bio-Rad).
Flow cytometry.
For surface staining, cells were incubated with antibodies at room temperature for 15mins or at 4°C for 30min. For intracellular staining, cells were fixed and permeabilized using Cytofix/CytoPerm (BD Biosciences) for 15mins at room temperature and washed with IX PermWash (BD Biosciences). Subsequent staining was performed using IX PermWash as staining and wash buffer. For CellTrace Violet (CTV) staining, cells were labeled with 5uM CTV (Thermo) before culture. In most assays, cells were stained with Zombie Aqua Live/Dead Discrimination dye (Biolegend) to gate out dead cells for analysis.
The following antibodies used for the flow cytometry analysis were obtained from BD Biosciences: APC-conjugated anti-CD4 (Clone RPA-T4), FITC-conjugated anti-CD8 (Clone RPA-T8), Alexa Fluor 700-conjugated anti-CD8 (Clone RPA-T8), PE-conjugated anti-IL17A (Clone SCPL1362), Alexa Fluor 647-conjugated anti-IFNy (Clone B27), Alexa Fluor 647-conjugated anti-CD271 (NGFR, Clone C40-1457), APC-conjugated anti-CD45RO (Clone UCHL1), PE-conjugated anti-CD45RA (Clone H100), PE-Cy7-conjugated anti-CD28 (Clone CD28.2), BV421 -conjugated anti- CD27 (Clone M-T271), PE-Cy7-conjugated anti-CD279 (PD1, Clone EH12.1),
BV711 -conjugated anti-Tim3 (Clone 7D3), PE-conjugated anti-CD223 (LAG3, Clone T47-530), Alexa Fluor 647-conjugated anti-Ki67 (Clone B56), PE-conjugated Annexin V, 7AAD, PE-conjugated rat-anti-mouse IgGl (Clone X56), APC-Cy7- conjugated anti-CD3 (Clone SK7), PE-conjugated anti-granzyme B (Clone GB11), PE-conjugated anti-CDlOl (Clone V7.1), PE-conjugated anti-TNF-a (Clone
MAB11), PE-conjugated anti-CD45 (Clone HI30), FITC-conjugated rat anti-mouse CD19 (Clone 1D3), APC-Cy7-conjugated hamster anti-mouse CD3e (Clone 145- 2C11), PE-conjugated rat anti-mouse Ly6G (Clone 1 A8), BV421 -conjugated rat anti mouse Ly6C (Clone AL21), APC-Cy7 rat anti-mouse CDl lb (Clone Ml/70), PerCP- Cy5.5-conjugated hamster anti-mouse CDl lc (Clone HL3), PerCP-Cy5.5 -conjugated rat anti-mouse CD4 (RM4-5), PE-conjugated rat anti-mouse Va2 TCR (Clone B20.1), FITC-conjugated rat anti-mouse Vb5.1 5.2 TCR (Clone MR9-4).
The following antibodies were obtained from Thermo: Alexa Fluor 647- conjugated anti-CD19 (Clone SJ25-C1), Alexa Fluor 594-conjugated anti-GFP (Polyclonal).
The following antibodies were obtained from Biolegend: BV711 -conjugated rat anti-mouse CD45 (Clone 30-F11), APC-conjugated rat anti-mouse CD8 (Clone 53-6.7), APC-conjugated rat anti-mouse CD64 (Clone X54-5/7.1), PE-Cy7- conjugated rat anti-mouse F4/80 (Clone BM8).
Flow cytometry data were collected on BD LSRFortessa (BD Biosciences) using BD FACSDIVA software and the flow data were analyzed by FlowJo software (v9.32, Tree Star).
Acquisition and processing of frozen patient tumor samples.
Frozen patient tumor specimens and matching adjacent normal tissues were obtained from the Tissue Procurement Facility at University of North Carolina at Chapel Hill. For RNA extraction, 20-30mg of frozen tissues were lysed using RLT buffer from RNeasy Plus Kit (Qiagen). To extract extracellular protein within interstitial fluid for IL23 ELISA, 40mg of frozen tissues were incubated in DPBS to obtain single cell suspension and the supernatant was collected. Total protein amount was quantified using Bradford assay (Bioard) and lOOug of protein was used for ELISA.
RNA Sequencing and GSEA.
Total RNA was extracted as described above and the library is prepared by the High Throughput Sequencing Facility (HTSF) at University of North Carolina at Chapel Hill using the KAPA Stranded mRNA-Seq Kit (Kapa Biosystem). 12 samples
were pooled and sequenced using HiSeq 4000 (Illumina) with high output paired end 50bp setting (>20xl06 reads per sample). Sequencing reads were aligned to the human genome (hg38) using STAR aligner (v2.4.2) [50] and subsequently quantified using Salmon (vO.8.2) [51] The differential expression analysis was conducted using DESeq2 (v3.8) [52] running on R (ver 3.5.0). Genes having >1 log2foldchange and an FDR rate less than 0.05 between Ctrl and p40-Td cells are being considered significant.
For visualization of PCA plot, genes with low expression (<20 counts across 6 samples (3 Ctrl and 3 p40-Td cells)) were filtered and data was transformed using regularized-logarithm transformation.
GSEA was performed using the GSEA v2 software (Broad Institute) on genes that are differentially expressed between day 5 activated Ctrl and p40-Td cells. Gene sets specified in this study are:
D AUER S T AT3 _T ARGET S UP (M12391) - STAT3 Upregulated Genes
[53];
D AUER S T AT3 _T ARGET S DN (M13696) - STAT3 Downregulated Genes [53]; and
HALLMARK HYPOXIA (M5891) - Genes upregulated in response to hypoxia.
Selected differentially expressed genes in STAT3 or hypoxia pathways identified in RNA-Seq were independently validated using qRT-PCR.
In vitro repetitive coculture assays.
2.5 x 106 tumor cells (LA-N-1, CHLA-255 and BXPC-3, all labeled with GFP) were seeded in tissue culture treated 12 well plate for 24 hrs. 5 x 104 (E:T = 1:5) or 1.25 xlO5 (E:T = 1:2) CAR T cells were then added to tumor cells. After 3-5 days (due to donor variability in cytotoxicity) when tumor cells were completely eradicated (Round 1, Rl). All cells in the well were collected and washed with PBS, resuspended in fresh media and added to a new plate seeded with 2.5 x 106 tumor cells for 3 days (Round 2, R2). This procedure was repeated for one more time, if applicable (Round 3, R3). At the end of each round, a duplicate well was collected for counting of
residual tumor cells (GFP+) and CAR T cells (CD3+) and other phenotypic analysis (Granzyme B, PD1, CD 101) on CAR T cells by flow cytometry.
For cytokine production assay after repetitive coculture, 3 x 106 tumor cells (LA-N-1) were irradiated at 40Gy before seeding to reduce tumor burden for T cells.
1 x 105 (E:T = 1 :3) CAR T cells were cocultured with tumors in this assay.
Mouse experiments
Male and female 6 - 8 weeks old NSG (NOD/SCID/IL-2Rnull) mice were purchased from the Animal Core Facility at UNC. Male and female 6 - 8 weeks old C57BL/6J and OT1 mice were purchased from The Jackson Laboratory. All the mice were housed in the Animal Core Facility at UNC. All mouse experiments were performed in accordance with UNC Animal Husbandry and Institutional Animal Care and Use Committee (IACUC) guidelines and were approved by UNC IACUC.
Xenogeneic mouse models.
For metastatic neuroblastoma models, CHLA-Ffluc (2 x 106) tumor cells were injected intravenously into 8-10 weeks old female NSG mice. Two weeks later mice are infused intravenously with GD2-specific CAR. Ctrl cells or CAR.p40-Td cells. Tumor progression is monitored weekly by bioluminescence imaging using IVIS lumina II in vivo imaging system (PerkinElmer). For rechallenge experiment, another dose of CHLA-Ffluc (3 x 106) cells were injected intravenously at 4 weeks post T cell infusion. Mice were euthanized when signs of discomfort were detected by the investigators or as recommended by the veterinarian who monitored the mice three times a week. Peripheral blood, spleen and liver (primary tumor site) were collected at indicated time points to measure the expansion and persistence of infused T cells (hCD45+hCD3+) by flow cytometry.
For orthotopic PD AC model, BxPC-3-Ffluc (1 x 105) tumor cells were suspended in 25 pL DPBS, mixed with 25 pL Matrigel (Corning) and surgically implanted into the pancreas of 8 - 10 weeks old male NSG mice as previously described [29] 14 days after tumor cell inoculation, control vector transduced T (Ctrl) cell, B7-H3 specific CAR. Ctrl or CAR.p40-Td cells were injected intravenously via tail injection (i.v.) (2 x 106 cells/mouse). Tumor growth was monitored weekly by
bioluminescence imaging using IVIS lumina II in vivo imaging system (PerkinElmer). In this model, the engraftment does not induce lethality of the mice even left untreated for more than 8 weeks post T cell infusion. The mice were arbitrarily considered dead in survival analysis when luciferase signal reached 15-fold over initial signal at week 0. All mice were euthanized at 8 weeks post T cell infusion and the peripheral blood, spleen and pancreas were collected to measure the persistence of infused T cells (hCD45+hCD3+) by flow cytometry.
Syngeneic mouse model.
B16-OVA cells (5 x 105 cells/mouse) were suspended in 50 uL DPBS mixed with 50 uL Matrigel (Corning) and were subcutaneously injected into left flank of 7 - 8 weeks male C57BL/6 mice. Seven days post tumor engraftment, OT-l-TCR T cells were infused intravenously. Tumor size was monitored every 2 - 3 days after T cell infusion using a caliper. Tumor volume was calculated as length x width x width x 0.5 as previously described [54], and mice with >1000cm3 were euthanized. After euthanization, blood, spleen, tumor and tumor dLN was collected for immunophenotyping by flow cytometry.
For the orthotopic PD AC model, the murine tumor cell line KPC-4662 was engineered to express mB7-H3, and implanted into pancreas of six week old C57BL/6J female mice by surgery (1 x 105 cells/mouse). Eighteen days post tumor cell implantation, mice were irradiated with 400 cGy to create a lymphodepleted environment. Two days post-irradiation, mice were infused i.v. with syngeneic T cells (1 x 107 cells/mouse). Tumor growth was monitored by US imaging biweekly.
Confocal microscopy.
Cell were collected and split in half. One half was stained with Alexa594- conjugated mouse anti-GFP antibody (Thermo) and Alexa647-conjugated anti-NGFR (BD Biosciences) while the other half were stained with Alexa594-conjugated mouse anti-GFP antibody and Alexa647-conjugated anti-CD 19 antibody (Thermo). Cells were stained for 30min at 4°C and subsequently washed with ice cold DPBS. Cells were then fixed with Cytofix (BD Biosciences) for lOmin at room temperature, washed with DPBS and loaded onto a glass slide using Cytospin Cytocentrifuge
(Thermo). Prolong Diamond Antifade Mountant with DAPI (Thermo) was applied before sealing the slide with a category 1.5 cover slip (Thermo). The slides were imaged using Zeiss LSM710 and image data were analyzed with FIJI (Image J).
To quantify binding of p40-GFP fusion protein on cell surface, the cell membrane was first defined based on Alexa647 signal (anti-NGFR or anti-CD 19 that marks p40-Td or ACD 19-Td cells, respectively). In parallel, an irrelevant area (either area with no cell or intracellular space) was selected as background area. The mean fluorescence intensity (MFI) of Alexa594 signal (anti-GFP) was measured on membrane area and background area and the surface binding of p40-GFP was calculated as MFI(membrane)-MFI(background).
Statistical Analysis
Student’s t test was used to determine statistically significant differences between 2 samples. When multiple comparison analyses were required, statistical significance was evaluated by ANOVA (one-way or two-way), followed by Sidak post-hoc analysis. If the data reflected measurement of 1 sample over time or under different conditions, repeated-measures ANOVA was used, followed by Sidak post- hoc analysis. All statistical analyses were performed with 2-tailed tests. Graph generation and statistical analyses were performed using GraphPad Prism, version 7 (GraphPad Software). A p value of less than 0.05 was considered statistically significant.
Reference:
1. Anderson, K.G., Stromnes, I.M. & Greenberg, P.D. Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies.
Cancer Cell 31, 311-325 (2017).
2. Garber, K. Driving T-cell immunotherapy to solid tumors. Nat Biotechnol 36, 215-219 (2018).
3. D'Angelo, S.P., et al. Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 (c259)T Cells in Synovial Sarcoma. Cancer Discov 8, 944-957 (2018).
4. Porter, D.L., Levine, B.L., Kalos, M., Bagg, A. & June, C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl JMed 365, 725-733 (2011).
5. Maude, S.L., Teachey, D.T., Porter, D.L. & Grupp, S.A. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 125, 4017-4023 (2015).
6. Sanmamed, M.F. & Chen, L. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175, 313-326 (2018).
7. Kershaw, M.H., Westwood, J.A. & Darcy, P.K. Gene-engineered T cells for cancer therapy. Nat Rev Cancer 13, 525-541 (2013).
8. Yao, X., etal. Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood 119, 5688-5696 (2012).
9. Hurton, L.V., el al. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proceedings of the National Academy of Sciences of the United States of America 113, E7788-E7797 (2016).
10. Hoyos, V., et al. Engineering CD19-specific T lymphocytes with interleukin- 15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 24, 1160-1170 (2010).
11. Waldmann, T.A., et al. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood 117, 4787-4795 (2011).
12. Berger, C., etal. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood 114, 2417-2426 (2009).
13. Di Stasi, A., et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl JMed 365, 1673-1683 (2011).
14. Kagoya, Y., et al. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat Med 24, 352-359 (2018).
15. Fraietta, J.A., et al. Determinants of response and resistance to CD 19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 24, 563-571 (2018).
16. Oppmann, B., et al. Novel pl9 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13, 715-725 (2000).
17. Duvallet, E., Semerano, L., Assier, E., Falgarone, G. & Boissier, M.C. Interleukin-23: a key cytokine in inflammatory diseases. Annals of medicine 43, 503- 511 (2011).
18. Ngiow, S.F., Teng, M.W. & Smyth, M.J. A balance of interleukin- 12 and -23 in cancer. Trends in immunology 34, 548-555 (2013).
19. Iwakura, Y. & Ishigame, H. The IL-23/IL-17 axis in inflammation. The Journal of clinical investigation 116, 1218-1222 (2006).
20. Aggarwal, S., Ghilardi, N., Xie, M.H., de Sauvage, F.J. & Gurney, A.L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin- 17. J Biol Chem 278, 1910-1914 (2003).
21. Xu, Y., etal. Glycolysis determines dichotomous regulation of T cell subsets in hypoxia. The Journal of clinical investigation 126, 2678-2688 (2016).
22. Langrish, C.L., etal. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201, 233-240 (2005).
23. Zhu, J., Yamane, H. & Paul, W.E. Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol 28, 445-489 (2010).
24. Langowski, J.L., et al. IL-23 promotes tumour incidence and growth. Nature 442, 461-465 (2006).
25. Grivennikov, S.I., et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 491, 254-258 (2012).
26. Gargett, T., et al. GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade. Mol Ther 24, 1135-1149 (2016).
27. Philip, M., et al. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature 545, 452-456 (2017).
28. Wherry, E.J. T cell exhaustion. Nat Immunol 12, 492-499 (2011).
29. Du, H.H., K; Ahn, S; Kren, N.P.; Montgomery, S.A.; Wang, XH; Tiruthani,
K; Mirlekar, R; Michaud, D; Greene, K; Herrera, S.G.; Sun, C; Chen, YH; Xu Y; Ma, XC; Ferrone, C.R.; Pylayeva-Gupta, Y; and Yeh, J.J.; Liu, RH; Savoldo, B; Ferrone,
S; Dotti, G. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 Via Chimeric Antigen Receptor T Cells Cancer Cell (2018).
30. Diaconu, T, et al. Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells. Mol Ther 25, 580-592 (2017).
31. Tey, S.K., Dotti, G., Rooney, C.M., Heslop, H.E. & Brenner, M.K. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 13, 913-924 (2007).
32. Teng, M.W., et al. Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. Cancer Res 72, 3987-3996 (2012).
33. Zhang, L., et al. IL-23 selectively promotes the metastasis of colorectal carcinoma cells with impaired Socs3 expression via the STAT5 pathway. Carcinogenesis 35, 1330-1340 (2014).
34. Lo, C.H., et al. Antitumor and antimetastatic activity of IL-23. Journal of immunology 171, 600-607 (2003).
35. Overwijk, W.W., et al. Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. Journal of immunology 176, 5213-5222 (2006).
36. Floss, D.M., Schroder, T, Franke, M. & Scheller, J. Insights into IL-23 biology: From structure to function. Cytokine Growth Factor Rev 26, 569-578 (2015).
37. Hor, Y.T., et al. A role for RUNX3 in inflammation-induced expression of IL23A in gastric epithelial cells. Cell Rep 8, 50-58 (2014).
38. Pulliam, S.R., Uzhachenko, R.V., Adunyah, S.E. & Shanker, A. Common gamma chain cytokines in combinatorial immune strategies against cancer. Immunol Lett 169, 61-72 (2016).
39. Rochman, Y., Spolski, R. & Leonard, W.J. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 9, 480-490 (2009).
40. Thurley, K., Gerecht, D., Friedmann, E. & Hofer, T. Three-Dimensional Gradients of Cytokine Signaling between T Cells. PLoS Comput Biol 11, el004206 (2015).
41. Oyler-Yaniv, A., et al. A Tunable Diffusion-Consumption Mechanism of Cytokine Propagation Enables Plasticity in Cell-to-Cell Communication in the Immune System. Immunity 46, 609-620 (2017).
42. Noman, M.Z., et al. The cooperative induction of hypoxia-inducible factor- 1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. Journal of immunology 182, 3510-3521 (2009).
43. Pawlus, M.R., Wang, L. & Hu, C.J. STAT3 and HIFlalpha cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells. Oncogene 33, 1670- 1679 (2014).
44. Song, L., et al. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma. The Journal of clinical investigation 117, 2702-2712 (2007).
45. Tarek, N., et al. Unlicensed NK cells target neuroblastoma following anti- GD2 antibody treatment. The Journal of clinical investigation 122, 3260-3270 (2012).
46. Caruana, T, et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med 21, 524-529 (2015).
47. Louis, C.U., et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118, 6050-6056 (2011).
48. Vera, T, et al. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 108, 3890-3897 (2006).
49. Xu, Y., et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 123, 3750-3759 (2014).
50. Dobin, A., et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15-21 (2013).
51. Patro, R, Duggal, G., Love, M.I., Irizarry, R.A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods 14, 417-419 (2017).
52. Love, M.I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15, 550 (2014).
53. Dauer, D.J., et al. Stat3 regulates genes common to both wound healing and cancer. Oncogene 24, 3397-3408 (2005).
54. Sockolosky, J.T., et al. Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. Science 359, 1037-1042 (2018).
Claims
1. A modified T cell comprising a PA2b p40 subunit.
2. The modified T cell of claim 1, wherein the T cell expresses p40.
3. The modified T cell of claim 1, wherein the T cell, upon activation, produces
IL23.
4. The modified T cell of claim 1, wherein the T cell is a CAR or TCR- engineered T cell.
5. The modified T cell of claim 1, wherein the T cell exhibits increased cell division.
6. The modified T cell of claim 1, wherein the T cell exhibits reduced apoptosis.
7. The modified T cell of claim 1, wherein the T cell exhibits increased T cell proliferation.
8. The modified T cell of claim 1, wherein the T cell, upon activation, exhibits increased STAT3 phosphorylation.
9. The modified T cell of claim 1, wherein the T cell, upon activation, exhibits differentiation expression of one or more STAT3 regulated genes selected from the group consisting of: SOX2, SOCS3, CEBPD, ABCA1, IFIT1, IFIT3, USP18, CDKN2B, and combinations thereof.
10. The modified T cell of claim 1, wherein the T cell, upon activation, activates the STAT3 pathway.
11. The modified T cell of claim 1, wherein the T cell expresses high levels of lytic enzyme granzyme B, as compared to a control cell.
12. The modified T cell of claim 1, wherein the T cell expresses reduced levels of exhaustion markers PD1 and/or CD101, as compared to a control cell.
13. The modified T cell of claim 1, wherein the T cell maintains production of IFNy and TNFa, as compared to a control cell.
14. The modified T cell of claim 1, wherein the T cell promotes enhanced tumor control and improved survival, as compared to a control cell.
15. The modified T cell of claim 1, wherein the T cell exhibits increased anti tumor activity.
16. The modified T cell of claim 1, wherein the T cell is a human T cell.
17. The modified T cell of claim 1, wherein the T cell is a non-human T cell.
18. The modified T cell of claim 17, wherein the T cell is a mouse T cell.
19. The modified T cell of claim 1, wherein the T cell comprising the IIA2b p40 subunit is produced by transducing a T cell with a retroviral supernatant comprising an IL l 2b p40 subunit.
20. A method of increasing T cell proliferation comprising modifying a T cell to comprise a IIA2b p40 subunit.
21. A method of treating cancer comprising administering to a subject a modified T cell comprising an IIA2b p40 subunit.
22. The method of claim 21, wherein upon activation of the modified T cell, the modified T cell produces IL23.
23. The method of claim 21, wherein the modified T cell exhibits increased anti tumor activity.
24. The method of claim 21, wherein the modified T cell exhibits increased T cell proliferation.
25. The method of claim 21, wherein the modified T cell promotes tumor regression.
26. The method of claim 21, wherein the modified T cell protects from tumor re challenge.
27. The method of claim 21, wherein the cancer is a melanoma.
28. The method of claim 21, wherein the cancer is a pancreatic cancer.
29. The method of claim 21, wherein the cancer is a hematologic malignancy.
30. The method of claim 21, wherein the cancer is a multiple myleloma.
31. The method of claim 21, wherein the cancer is a carcinoma or a sarcoma.
32. The method of claim 21, wherein the subject is a mammal.
33. The method of claim 21, wherein the subject is human.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/762,360 US20230127263A1 (en) | 2019-09-20 | 2020-09-20 | Modified t cells and methods of preparing the same |
EP20864588.7A EP4031654A4 (en) | 2019-09-20 | 2020-09-20 | Modified t cells and methods of preparing the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962903717P | 2019-09-20 | 2019-09-20 | |
US62/903,717 | 2019-09-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021055915A1 true WO2021055915A1 (en) | 2021-03-25 |
Family
ID=74884719
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2020/051713 WO2021055915A1 (en) | 2019-09-20 | 2020-09-20 | Modified t cells and methods of preparing the same |
Country Status (3)
Country | Link |
---|---|
US (1) | US20230127263A1 (en) |
EP (1) | EP4031654A4 (en) |
WO (1) | WO2021055915A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8298790B2 (en) * | 2007-05-14 | 2012-10-30 | Chae-Ok Yun | Methods for effectively coexpressing IL-12 and IL-23 |
US20170283775A1 (en) * | 2010-12-09 | 2017-10-05 | The Trustees Of The University Of Pennsylvania | Compositions and Methods for Treatment of Cancer |
WO2019076489A1 (en) * | 2017-10-19 | 2019-04-25 | Cellectis | Targeted gene integration of crs inhibitor genes for improved immune cells therapy |
-
2020
- 2020-09-20 EP EP20864588.7A patent/EP4031654A4/en active Pending
- 2020-09-20 WO PCT/US2020/051713 patent/WO2021055915A1/en unknown
- 2020-09-20 US US17/762,360 patent/US20230127263A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8298790B2 (en) * | 2007-05-14 | 2012-10-30 | Chae-Ok Yun | Methods for effectively coexpressing IL-12 and IL-23 |
US20170283775A1 (en) * | 2010-12-09 | 2017-10-05 | The Trustees Of The University Of Pennsylvania | Compositions and Methods for Treatment of Cancer |
WO2019076489A1 (en) * | 2017-10-19 | 2019-04-25 | Cellectis | Targeted gene integration of crs inhibitor genes for improved immune cells therapy |
Non-Patent Citations (6)
Title |
---|
CHEN YUHUI, SUN CHUANG, LANDONI ELISA, METELITSA LEONID, DOTTI GIANPIETRO, SAVOLDO BARBARA: "Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and lnterteukin-15", CLINICAL CANCER RESEARCH, vol. 25, no. 9, 7 January 2019 (2019-01-07), pages 2915 - 2924, XP055808181 * |
CHMIELEWSKI, M ET AL.: "IL -12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression", CANCER RESEARCH, vol. 71, no. 17, 8 July 2011 (2011-07-08), pages 5697 - 5706, XP055185302, DOI: 10.1158/0008-5472.CAN-11-0103 * |
MA XINGCONG, SHOU PEISHUN, SMITH CHRISTOF, CHEN YUHUI, DU HONGWEI, SUN CHUANG, PORTERFIELD KREN NANCY, MICHAUD DANIEL, AHN SARAH, : "ED SUM: The efficacy of chimeric antigen receptor (CAR)-T cells in solid tumor models is enhanced by IL 23 engineering: Interfeukin-23 engineering improves CAR-T cell function in solid tumors", NATURE BIOTECHNOLOGY, vol. 38, no. 4, 2020, pages 448 - 459, XP037086863, DOI: 10.1038/s4158/-019-0398-2 * |
PARHAM CHRISTI, CHIRICA MADALINE, TIMANS JACQUELINE, VAISBERG ELENA, TRAVIS MARILYN, CHEUNG JEANNE, PFLANZ STEFAN, ZHANG REBECCA, : "A Receptor for the Heterodimeric Cytokine IL -23 Is Composed of IL-12Rbeta1 and a Novel Cytokine Receptor Subunit, IL-23R1", THE JOURNAL OF IMMUNOLOGY, vol. 168, no. 11, 1 June 2002 (2002-06-01), pages 5699 - 5708, XP002480759 * |
See also references of EP4031654A4 * |
SIMMONS, A ET AL.: "Retroviral Transduction of T Cells and T Cell Precursors", METHODS IN MOLECULAR BIOLOGY, vol. 1323, 2016, pages 99 - 108, XP055808202 * |
Also Published As
Publication number | Publication date |
---|---|
US20230127263A1 (en) | 2023-04-27 |
EP4031654A1 (en) | 2022-07-27 |
EP4031654A4 (en) | 2023-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ma et al. | Interleukin-23 engineering improves CAR T cell function in solid tumors | |
JP2021176863A (en) | Methods for enhancing potency of immune cells | |
KR20220068240A (en) | Combination of cancer therapy and cytokine-modulating therapy for the treatment of cancer | |
CN111727045A (en) | Compositions and methods for inhibiting T cell depletion | |
Wu et al. | CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma | |
JP7239463B2 (en) | Compositions and methods for cancer immunotherapy | |
CN111386128A (en) | Combination therapy for immunomodulation | |
US20240058446A1 (en) | Chimeric tim4 receptors and uses thereof | |
CN111372584A (en) | Dual inhibitors of the TIM-3 and PD-1 pathways | |
US20230114107A1 (en) | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly | |
JP2022500448A (en) | Methods of regulating regulatory T cells and inhibiting tumor growth | |
EP3016683A1 (en) | Soluble mic neutralizing monoclonal antibody for treating cancer | |
IL303761A (en) | Treatment of cancer with nk cells and a cd20 targeted antibody | |
EP3228701A1 (en) | Method for preparing lymphocytes capable of infiltrating a solid tumor, lymphocytes obtainable by said method and uses thereof | |
KR20190098995A (en) | Oxabicycloheptane for the regulation of immune responses | |
AU2020350221A1 (en) | Combination cancer therapy and cytokine control therapy for cancer treatment | |
US20230127263A1 (en) | Modified t cells and methods of preparing the same | |
US20210355221A1 (en) | Targeting the Non-Canonical NFkB Pathway in Cancer Immunotherapy | |
US20240108721A1 (en) | Dual targeting chimeric antigen receptors | |
JP2020510681A (en) | Compositions and methods for treating cancer using anti-renalase and anti-PD-1 antibodies | |
JP7407452B2 (en) | Medicines for the treatment and/or prevention of cancer | |
WO2023147564A2 (en) | Natural killer t-cells and methods of using the same | |
Ma et al. | ED SUM: The efficacy of chimeric antigen receptor (CAR)-T cells in solid tumor models is enhanced by IL23 engineering.: Interleukin-23 engineering improves CAR-T cell function in solid tumors | |
US20240156911A1 (en) | Lung-cancer specific t cell dysfunction | |
US20230241141A1 (en) | Pharmaceutical composition for preventing or treating cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20864588 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020864588 Country of ref document: EP Effective date: 20220420 |